Characterisation of apoptosis-stimulating p53 binding protein 2 (ASPP2) as a new substrate for asparaginyl hydroxylation by Janke, Kirsten
  
 
 
 
Characterisation of apoptosis-stimulating p53 
binding protein 2 (ASPP2) as a new substrate for 
asparaginyl hydroxylation 
 
 
Inaugural-Dissertation 
zur 
Erlangung des Doktorgrades 
Dr. rer. nat. 
 
 
 
der Fakultät für 
Biologie 
an der 
Universität Duisburg-Essen 
 
 
vorgelegt von 
Kirsten Janke 
 
 
 
aus Wuppertal 
April, 2013
Die der vorliegenden Arbeit zugrunde liegenden Experimente wurden am Institut für 
Physiologie AG Metzen, Universitätsklinikum Essen, Universität Duisburg-Essen 
durchgeführt. 
 
1. Gutachter: Prof. Dr. Eric Metzen 
2. Gutachter: Prof. Dr. Verena Jendrossek 
3. Gutachter: - 
Vorsitzender des Prüfungsausschusses: Prof. Dr. Michael Ehrmann 
Tag der mündlichen Prüfung: 04.09.2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Für Stefan 
 
 I 
 
 Table of Contents 
Table of Contents 
1 INTRODUCTION ..................................................................................... 1 
1.1 2-OXOGLUTARATE-DEPENDENT DIOXYGENASES .........................................1 
1.1.1 Cellular function ..............................................................................................1 
1.1.2 Hydroxylation mechanism ...............................................................................1 
1.1.3 Hypoxia-inducible factor (HIF) hydroxylation .................................................3 
1.1.4 Ankyrin repeat domain (ARD) hydroxylation ..................................................5 
1.1.4.1 ARD structure .............................................................................................5 
1.1.4.2 ARD hydroxylation catalysed by FIH-1 .......................................................6 
1.2 APOPTOSIS-STIMULATING P53-BINDING PROTEINS (ASPPS) .......................9 
1.2.1 General characteristics .....................................................................................9 
1.2.2 ASPP1 and ASPP2 ..........................................................................................9 
1.2.2.1 Structure, function and regulation ...............................................................9 
1.2.2.2 Stimulation of p53-dependent apoptosis by ASPP1 and ASPP2 ................. 12 
1.2.2.3 Mouse models of ASPP1 and ASPP2 deficiency......................................... 13 
1.2.2.4 ASPP1 and ASPP2 - beyond p53 regulation .............................................. 14 
1.2.3 iASPP............................................................................................................ 15 
1.2.3.1 Structure, function and regulation ............................................................. 15 
1.2.3.2 Inhibition of p53-dependent apoptosis and cell cycle arrest by iASPP ....... 16 
1.2.3.3 iASPP knockout mouse model .................................................................... 17 
1.2.3.4 iASPP - beyond p53 regulation.................................................................. 17 
1.2.4 ASPPs and cancer.......................................................................................... 18 
1.3 AIM OF THE STUDY ..................................................................................... 20 
2 MATERIAL AND METHODS ............................................................... 21 
2.1 MATERIAL .................................................................................................. 21 
2.1.1 Reagents and consumables ............................................................................ 21 
2.1.2 Technical devices .......................................................................................... 21 
2.1.3 Buffers and media ......................................................................................... 22 
2.1.4 Bacterial strains and eukaryotic cell lines ...................................................... 23 
2.1.5 Plasmids, shRNA sequences and PCR primers .............................................. 24 
2.1.6 Antibodies ..................................................................................................... 27 
2.2 METHODS.................................................................................................... 28 
2.2.1 Transformation of bacteria............................................................................. 28 
2.2.2 Preparation of plasmid DNA ......................................................................... 28 
2.2.3 Recombinant protein expression .................................................................... 28 
2.2.4 Polymerase Chain Reaction (PCR) ................................................................ 29 
2.2.4.1 Standard PCR ........................................................................................... 29 
2.2.4.2 Overlap PCR for mutagenesis ................................................................... 29 
2.2.5 In vitro DNA recombination .......................................................................... 30 
2.2.6 Agarose gel electrophoresis ........................................................................... 30 
2.2.7 Cell culture .................................................................................................... 30 
 II 
 
 Table of Contents 
2.2.7.1  Culture conditions for eukaryotic cell lines............................................... 30 
2.2.7.2  Cryopreservation of eukaryotic cell lines .................................................. 31 
2.2.7.3  Transfection of cell cultures ..................................................................... 31 
2.2.7.4  Lentivirus production in HEK293T cells ................................................... 31 
2.2.7.5  Lentiviral transduction of cell cultures ..................................................... 31 
2.2.7.6  Irradiation, chemotherapeutic and hypoxic treatment of cell cultures ....... 32 
2.2.7.7  Proliferation measurement ....................................................................... 32 
2.2.7.8  Scratch assay ........................................................................................... 32 
2.2.7.9  Adhesion assay ......................................................................................... 33 
2.2.7.10  Pulse-chase labelling of cellular proteins ................................................. 33 
2.2.8 Purification of recombinant proteins .............................................................. 34 
2.2.8.1 Nickel affinity purification ......................................................................... 34 
2.2.8.2 Glutathione affinity purification ................................................................ 34 
2.2.9 In vitro transcription and translation of proteins ............................................. 35 
2.2.10 Hydroxylase activity assay ............................................................................ 35 
2.2.11 Sample preparation for mass spectrometry (MS) analysis .............................. 35 
2.2.12 LC-MS/MS analysis ...................................................................................... 36 
2.2.13 In vitro protein interaction ............................................................................. 37 
2.2.14 Determination of protein concentration .......................................................... 37 
2.2.15 Immnunoprecipitation of protein complexes .................................................. 37 
2.2.16 SDS polyacrylamide gel electrophoresis (PAGE) and Western blotting ......... 38 
2.2.17 Caspase-3 activity assay ................................................................................ 38 
2.2.18 Immunofluorescence microscopy .................................................................. 39 
2.2.19 Statistical analysis ......................................................................................... 39 
3 RESULTS ................................................................................................ 40 
3.1 SEQUENCE SIMILARITIES BETWEEN ASPPS AND KNOWN FIH-1 
  SUBSTRATES ................................................................................................ 40 
3.2 FIH-1-DEPENDENT HYDROXYLATION OF ASPPS IN VITRO ........................ 43 
3.2.1 ASPP2 derived FIH-1 substrates .................................................................... 43 
3.2.2 Protein expression and purification ................................................................ 44 
3.2.3 FIH-1-dependent hydroxylation of ASPP2 in vitro ........................................ 45 
3.2.4 ASPP peptide design ..................................................................................... 48 
3.2.5 FIH-1-dependent hydroxylation of ASPP peptides in vitro ............................ 50 
3.3 FIH-1 DEPENDENT HYDROXYLATION OF ASPP2 IN CELLS ........................ 52 
3.4 FIH-1-ASPP2 INTERACTION IN VITRO ....................................................... 55 
3.5  IMPACT OF FIH-1-DEPENDENT HYDROXYLATION OF ASPP2 .................... 57 
3.5.1 FIH-1 and ASPP2 co-localise in cells ............................................................ 57 
3.5.2 ASPP2 protein stability ................................................................................. 57 
3.5.3 Cell proliferation ........................................................................................... 60 
3.5.4 Apoptosis ...................................................................................................... 61 
3.5.5 Protein interaction ......................................................................................... 67 
3.5.6 Adhesion and migration ................................................................................. 72 
 III 
 
 Table of Contents 
4 DISCUSSION .......................................................................................... 75 
4.1 ASPP2 IS HYDROXYLATED BY FIH-1 AT N986 ........................................... 75 
4.2 SUBSTRATE RECOGNITION BY FIH-1 ......................................................... 77 
4.2.1 Differences between HIF-1α and ASPP2 ....................................................... 77 
4.2.2 ASPP2 but not iASPP is hydroxylated by FIH-1 ............................................ 79 
4.2.3 Implications for the identification of new substrates ...................................... 80 
4.3 IMPACT OF FIH-1-DEPENDENT HYDROXYLATION OF ASPP2 .................... 82 
4.3.1 ASPP2 protein stability is not regulated by FIH-1 .......................................... 82 
4.3.2 Cell proliferation and apoptosis are not affected by FIH-1 ............................. 83 
4.3.3 Protein interactions of ASPP2 are regulated by FIH-1 ................................... 85 
4.3.4 Physiological effects of altered protein interactions of ASPP2 – future 
  perspectives ................................................................................................... 87 
5  SUMMARY ............................................................................................. 90 
6 ZUSAMMENFASSUNG ......................................................................... 92 
7 REFERENCES ........................................................................................ 94 
8 APPENDIX ............................................................................................ 108 
8.1 ABBREVIATIONS ....................................................................................... 108 
8.2 LIST OF FIGURES ...................................................................................... 112 
8.3 LIST OF TABLES ........................................................................................ 114 
8.4 ACKNOWLEDGEMENT ............................................................................... 115 
8.5 CURRICULUM VITAE ................................................................................ 116 
8.6 PUBLICATION LIST ................................................................................... 118 
8.7 DECLARATIONS ........................................................................................ 120 
 
 1 
 
1 Introduction 
1 Introduction 
1.1 2-Oxoglutarate-dependent dioxygenases 
1.1.1 Cellular function 
Hydroxylation is a protein modification of vital importance for eukaryotic organisms. For 
example prolyl and lysyl hydroxylation are essential for the stabilisation of collagen triple 
helices and thereby mediate the stability of connective tissue, which mainly consists of 
collagen (Uitto and Lichtenstein, 1976). Recently, hydroxylation has been shown to provide a 
mechanism for histone demethylation where hydroxylation of the methyl group was found to 
remove the histone modification in the course of the reaction (Loenarz and Schofield, 2011). 
Hydroxylated amino acids can also mark proteins for ubiquitination and thus modulate protein 
stability as exemplified by prolyl hydroxylation of hypoxia-inducible factor (HIF) (Masson 
and Ratcliffe, 2003). Until recently, posttranslational hydroxylation of cellular proteins was 
thought to be uncommon, but over the last decade advances in mass spectrometry and 
proteomic analyses facilitated the detection of this protein modification and led to the 
discovery of a number of new hydroxylase substrates with partly unknown function to date 
(Loenarz and Schofield, 2011). 
 
1.1.2 Hydroxylation mechanism 
All the hydroxylation reactions outlined above are catalyzed by Fe(II)- and 2-oxoglutarate-
dependent dioxygenases which are involved in a variety of essential cellular functions 
(Loenarz and Schofield, 2011). The mechanism of the reaction catalyzed by these enzymes is 
highly conserved. First, the co-substrate 2-oxoglutarate (2-OG) binds to the active site of the 
enzyme, occupying two coordination sites of the Fe(II) which is attached to the enzyme via a 
facial triad and coordinated by three water molecules in the absence of substrates. 
Subsequently, binding of the primary substrate displaces the residual water molecule usually 
coordinating the iron which leaves one coordination site for oxygen to bind leading to the 
oxidative decarboxylation of 2-OG (Fig. 1 A) (Schofield and Ratcliffe, 2004). This reaction 
generates carbon dioxide, succinate and a strongly reactive Fe(IV)=O ferryl species that 
finally oxidizes the primary substrate via intermediate formation of a substrate radical and a 
Fe(III)-OH species (Dann and Bruick, 2005; Gorres and Raines, 2010).  
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2-oxoglutarate
N-oxalylglycine
dimethyloxalylglycine
A 
 
 
 
 
 
 
 
 
 
B  
Fig. 1: Hydroxylation by Fe(II)- and 2-oxoglutarate-dependent 
dioxygenases. (A) Mechanism of the hydroxylation reaction catalysed by 
Fe(II)- and 2-oxoglutarate-dependent dioxygenases (modified from  
Schofield and Ratcliffe, 2004). Binding of 2-oxoglutarate (2-OG) to the 
active site of the enzyme displaces two out of three water molecules that 
coordinate the Fe(II) which is attached to the enzyme via a facial triad (H199, 
D201, and H279 for factor-inhibiting hypoxia-inducible factor 1 (FIH-1)). 
Subsequent binding of the substrate replaces the residual water molecule 
which results in a vacant coordination site for oxygen inducing the oxidative 
decarboxylation of 2-OG. The decarboxylation step produces a strongly 
reactive Fe(IV)=O ferryl species which oxidises the substrate releasing 
succinate and the hydroxylated peptide substrate. (B) Chemical structure of 
2-OG and derivatives used as inhibitors of Fe(II)- and 2-oxoglutarate-
dependent dioxygenase activity. 
 
 
Hydroxylation by Fe(II)- and 2-oxoglutarate-dependent dioxygenases can be inhibited by 
addition of an alternative compound, N-oxalylglycine (NOG), which competes with 2-OG for 
binding to the enzyme. Binding of NOG to the active site of the enzyme still allows the 
primary substrate to attach to the enzyme but decarboxylation is prevented by an amide group 
leading to a trapped enzyme substrate complex. The same mechanism applies to the  
cell-penetrating form of NOG, dimethyloxalylglycine (DMOG), which can be applied to 
living cells (Fig. 1 B) (Epstein et al., 2001; Jaakkola et al., 2001). 
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1.1.3 Hypoxia-inducible factor (HIF) hydroxylation 
 
A 
 
 
 
 
 
 
B 
 
 
Fig. 2: Regulation of HIF-1 by Fe(II)- and 2-oxoglutarate-dependent dioxygenases. (A) Regulation of HIF-1 
activity by posttranslational hydroxylation under normoxic and hypoxic conditions. Prolyl hydroxylation of 
HIF-1α at P402 and P564 by prolyl hydroxylase domain containing enzymes (PHDs) triggers interaction with a 
von Hippel-Lindau (VHL) dependent E3 ubiquitin ligase mediating HIF-α ubiquitination and proteasomal 
degradation. Asparaginyl hydroxylation at N803 by FIH-1 prevents the interaction of HIF-1 with transcriptional 
co-activators, e.g. p300/CREB binding protein (CBP), and thereby represses HIF-1 target gene transcription. 
Under hypoxic conditions enzyme activity of PHDs and FIH-1 is suppressed which leads to the activation of the 
transcription factor. (B) Domain structure of HIF-1α. Hydroxylation sites are indicated by asterisks.  
Ub, ubiquitin; bHLH, basic-helix-loop-helix domain; PAS, Per-Arnt-Sim domain; ODD, oxygen-dependent 
degradation domain; NTAD, N-terminal transactivation domain; CTAD, C-terminal transactivation domain; 
HRE, hypoxia-reponsive element. 
 
As outlined above, hydroxylation reactions mediated by Fe(II)- and 2-oxoglutarate-dependent 
dioxygenases are involved in a variety of essential cellular functions. The regulation of HIF 
by these enzymes is mediated by modulation of protein interactions on the molecular level 
(Fig. 2 A). On one hand, HIF-α prolyl hydroxylation by prolyl hydroxylase domain containing 
enzymes (PHDs) triggers interaction with the substrate recognition subunit of the E3 ubiquitin 
ligase responsible for HIF-α degradation, the von Hippel-Lindau (VHL) protein. PHD activity 
thereby induces the proteasomal degradation of HIF-α (Kaelin and Ratcliffe, 2008).  
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On the other hand, HIF asparaginyl hydroxylation by Factor Inhibiting HIF-1 (FIH-1) impairs 
the interaction with the transcriptional co-activator p300/CREB binding protein (CBP) and 
thereby decreases transcriptional activity (Lisy and Peet, 2008). Both regulatory processes 
function independently because prolyl and asparaginyl hydroxylation occur at amino acid 
residues in different regulatory domains of HIF-α. PHDs hydroxylate two proline residues in 
the oxygen-dependent degradation domain (ODD) while FIH-1 targets one asparagine in the 
C-terminal transactivation domain (CTAD) (Fig. 2 B). Therefore, two oxygen-dependent 
mechanisms ensure the control of HIF activity, on one hand, HIF stability is regulated by 
PHDs, on the other FIH-1-dependent hydroxylation limits transcriptional activity independent 
of the degradation machinery (Kaelin and Ratcliffe, 2008; Semenza, 2012).  
The corresponding regulatory domains, CTAD and ODD, were reported very early for the 
transcription factor (Pugh et al., 1997) while the mechanism of HIF hydroxylation and the 
corresponding enzymes, FIH-1 and PHDs, was illuminated later (Epstein et al., 2001; Mahon 
et al., 2001; Hewitson et al., 2002; Lando et al., 2002a). Remarkably, the effect of asparaginyl 
hydroxylation on HIF activity seems to depend on the specific target gene. While carbonic 
anhydrase 9 (Ca-9) and glucose transporter 1 (Glut-1) expression can be inhibited by FIH-1 
activity, expression levels of phosphoglycerate kinase 1 (PGK1) and Bcl-2/adenovirus E1B 
19kDa interacting protein 3 (Bnip3) do not differ in the presence or absence of the enzyme. 
HIF-dependent transactivation of the latter genes is exclusively regulated by the stability of 
the transcription factor and thus by HIF prolyl hydroxylation (Dayan et al., 2006).  
Although FIH-1 and PHDs both belong to the family of Fe(II)- and 2-oxoglutarate-dependent 
dioxygenases, and share the same set of co-factors required for the hydroxylation reaction, 
there are also substantial differences between the enzymes. FIH-1 has a higher affinity for 
molecular oxygen in comparison to PHDs suggesting that mild hypoxic conditions still allow 
FIH-1-dependent hydroxylation while PHDs are already inactive (Koivunen et al., 2004). 
This might be of interest because not all HIF target genes were found to be equally sensitive 
to hydroxylation of the CTAD. Additionally the substrate specificity of PHDs appears to be 
more restricted as compared to FIH-1 because very few alternative PHD substrates could be 
identified so far (Cummins et al., 2006; Koditz et al., 2007) while several FIH-1 substrates 
apart from HIF have been reported (Cockman et al., 2009b; Coleman and Ratcliffe, 2009). In 
contrast to the transcription factor all these substrates are hydroxylated by FIH-1 in a 
conserved protein interaction motif termed ankyrin repeat domain (ARD). 
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1.1.4 Ankyrin repeat domain (ARD) hydroxylation 
1.1.4.1 ARD structure 
 
A     B 
 
 
 
 
 
 
Fig. 3: Ankyrin repeat domain structure of ASPP2. Front (A) and side view (B) schematic representations of 
the solution structure of the ankyrin repeat domain (ARD) of apoptosis-stimulating p53 binding protein 2 
(ASPP2) (PDI entry 4A63_B) (Canning et al., 2012). The antiparallel α-helices (cylinders) of multiple repeats 
show the typical stacked conformation of the ARD structure. The loop region projects outward in a 90° angle 
and forms β-sheet structures which are indicated by arrows. The scheme was generated using the Cn3D 4.3 
macromolecular structure viewer (NCBI). 
 
The ARD consists of a motif of approximately 33 amino acids in length, the single ankyrin 
repeat, which recurs from one to 34 times within the domain. Each single ankyrin repeat 
adopts a helix-turn-helix conformation with two antiparallel α-helices and a connecting loop 
pointing outward in a hairpin-like 90° angle to enable formation of β-sheet structures 
comprising the loops of multiple repeats (Fig. 3) (Mosavi et al., 2004; Li et al., 2006). The  
α-helices of multiple repeats are stacked together in a helix bundle which is stabilised by 
hydrophobic interactions and hydrogen bonds. In contrast to the helix bundle, the β-sheet 
formed by the hairpin-like loop regions of multiple repeats adopts a very flexible 
conformation. Therefore, it is not surprising that protein interaction interfaces composed of 
ARDs often comprise the β-sheet structures of the stacked repeats (Mosavi et al., 2004; Li et 
al., 2006). This composition allows a variety of possible conformations and thereby many 
interaction partners despite the high conservation of the ankyrin repeat primary sequence but 
also specificity of protein interactions for different ARD-containing proteins (Mosavi et al., 
2004). Regarding the secondary structure, ARDs exhibit less long-range contacts of the 
polypeptide chain as compared to globular domains, and the stacking of the single repeats 
determines the secondary structure as well as intra- and inter-repeat short-range contacts.  
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D G R T P L H L A A R N G H L E V V K L L L E H G A D V N A R D K
α-helix 1 α-helix 2 loop
1.1.4.2 ARD hydroxylation catalysed by FIH-1  
 
 
 
 
Fig. 4: Ankyrin repeat domain consensus sequence (modified from Schmierer et al., 2010). 33 amino acid 
consensus sequence of the human ankyrin repeat with the hydroxylation site for FIH-1 indicated in red. 
Secondary structure elements are shown below the sequence. 
 
Although this suggests an intrinsic stability of each single repeat and thus a sequential folding 
mechanism with multiple transition states, the equilibrium folding and unfolding of  
ARD-containing proteins is quite similar to that of proteins adopting predominantly globular 
structures with a two-state transition. This implies that coupling mechanisms between the 
neighbouring repeats may play a role in ARD folding kinetics which is particularly interesting 
as some ARD-containing proteins e.g. nuclear factor-κ-B (NF-κB) inhibitor alpha (IκBα) 
seem not to fold until binding of the interaction partner. Thus the ARD structure notably 
contributes to binding kinetics of protein interactions with ARD-containing proteins. This is 
of particular importance for cellular signal transduction because ARD-containing proteins are 
involved in almost every cellular signalling pathway and 6% of eukaryotic protein sequences 
contain ankyrin repeats (Mosavi et al., 2004; Barrick et al., 2008). 
Hydroxylation of ARDs by FIH-1 as reported for several proteins (Table 1) may influence the 
stability of the ARD or modify the protein interactions mediated by the domain as the 
hydroxylation site for FIH-1 is localised in the loop between the single repeats which is often 
part of interaction interfaces (Fig. 4). Although the ARD is highly conserved, certainly not all 
ARDs are targeted by FIH-1.  
Nonetheless, not only asparaginyl but also aspartyl and histidinyl hydroxylation by FIH-1 has 
been demonstrated in several ARD proteins as summarised in Table 1. A fraction of these 
substrates were identified by in vitro quantification of enzyme activity on short peptides or 
protein fragments containing the hydroxylation site using 2-OG decarboxylation assays or 
mass spectrometry analysis. However, for some of the substrates hydroxylation of 
overexpressed or even the endogenous protein by FIH-1 has been demonstrated by mass 
spectrometry in cells (Table 1).  
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Table 1: ARD-containing FIH-1 substrates verified experimentally in vitro and in cells.  
Substrate Hydroxylation site(s) In vitro In cells Reference(s) 
p19-INK4d N101 peptide --- (Cockman et al., 2006) 
ILK-1 N94 peptide --- (Cockman et al., 2006) 
FEM1β N526 peptide --- (Cockman et al., 2006) 
FGIF N168 peptide --- (Cockman et al., 2006) 
GABP-β1 N98 peptide --- (Cockman et al., 2006) 
Gankyrin N100 peptide --- (Cockman et al., 2006) 
Myotrophin N62 peptide --- (Cockman et al., 2006) 
Tankyrase-1 
N864 
H396, H711 
peptide --- 
(Cockman et al., 2006; 
Yang et al., 2011a) 
IκBα N210, N244 full-length protein endogenous (Cockman et al., 2006) 
p105 N678 protein fragment 
exogenous 
full length 
(Cockman et al., 2006) 
ASB4 N246 --- 
exogenous 
full length 
(Ferguson et al., 2007) 
RNaseL N233 --- 
exogenous 
full length 
(Cockman et al., 2009a) 
Tankyrase-2 
N203, N271, N427, 
N518, N586, N671, 
N706, N739 
H238, H553 
--- 
exogenous 
full length 
(Cockman et al., 2009a; 
Yang et al., 2011a) 
Rabankyrin-5 
N316, N649, N752, 
N797 
--- 
exogenous 
full length 
(Cockman et al., 2009a; 
Singleton et al., 2011) 
MYPT1 N67, N100, N226 --- endogenous (Webb et al., 2009) 
hNotch1 N1956 protein fragment endogenous (Coleman et al., 2007) 
mNotch1 N1945, N2012 protein fragment 
exogenous 
fragment 
(Wilkins et al., 2009) 
mNotch2 N1902, N1969 protein fragment --- (Wilkins et al., 2009) 
mNotch3 N1867, N1934 protein fragment --- (Wilkins et al., 2009) 
AnkyrinR 
N105, N138, N233, 
N464, N629, N728 
protein fragment endogenous (Yang et al., 2011b) 
GTAR D1380 peptide --- (Yang et al., 2011b) 
hMASK D1352 peptide --- (Yang et al., 2011b) 
GABP-β2 H131 peptide --- (Yang et al., 2011a) 
TRPV4 H265 peptide --- (Yang et al., 2011a) 
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The function of ARD hydroxylation by FIH-1 could not be revealed yet, although very crucial 
cellular signalling components like IκBα, Notch1 and p105 are among the ARD-containing 
substrates of FIH-1 (Cockman et al., 2006; Coleman et al., 2007). Structural studies on 
recombinant ARD consensus proteins containing three repeats demonstrated that the thermal 
stability of the ARD fold of these artificial proteins was increased upon hydroxylation by 
FIH-1 (Hardy et al., 2009; Kelly et al., 2009). Recently, a similar effect on the thermal 
stability was demonstrated for the repeats 13-24 of AnkyrinR. Binding of this protein 
fragment to an interaction partner, cytoplasmic domain of band 3 (CDB3), was decreased 
upon co-expression of FIH-1 (Yang et al., 2011b). This suggests a similar inhibitory effect of 
FIH-1-dependent hydroxylation on protein interaction as observed for HIF-1α-p300/CBP 
binding (Lando et al., 2002b). However, further studies are required to demonstrate that these 
results can be transferred to the endogenous full length protein.  
Considering the abundance of ARD-containing proteins in the cell it is also likely that the 
function of ARD hydroxylation might be the sequestration of the enzyme from HIF 
regulation. Supporting this hypothesis several studies demonstrate that co-expression of ARD 
substrates increases HIF reporter gene activity in transfected cells through competition for 
FIH-1-dependent hydroxylation (Coleman et al., 2007; Zheng et al., 2008; Webb et al., 2009). 
Furthermore, a predictive kinetic model on hydroxylation of HIF-α in the absence and 
presence of ARD substrates supports this hypothesis (Schmierer et al., 2010).  
Very recently, transgenic mice overexpressing one of the ARD substrates, Gankyrin, 
specifically in hepatocytes were found to exhibit increased HIF-1 activity leading to increased 
vascular tumorigenesis due to the disruption of FIH-1-mediated HIF-1 inhibition (Liu et al., 
2013). Quantitative mass spectrometry analyses on overexpressed ARD substrates in vitro 
show different levels of hydroxylation ranging from about 20% for Ranbankyrin N316 to 
about 90% for the murine Notch1 ARD which demonstrates a site-specific regulation by 
FIH-1 (Singleton et al., 2011). However, to date it is not known how effective the enzyme can 
hydroxylate endogenous ARD proteins and HIF-α in vivo. Thus, it is still unclear whether the 
abundance of ARD substrates in fact limits the hydroxylation of HIF-α and thereby 
contributes to HIF regulation.  
Nevertheless, the abundance of cellular ARD-containing proteins and the high conservation of 
the ankyrin repeat sequence and structure suggest that ARD-hydroxylation might be a 
common protein modification and additional ARD-containing substrates have not been 
identified for FIH-1 to date. Interestingly, FIH-1-deficient mice do not exhibit aberrant HIF 
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activity but rather show a dysregulation in the energy metabolism (Zhang et al., 2010). 
Moreover, FIH-1 suppression in two different cancer cell lines has been shown to induce 
p53-dependent expression of the cyclin-dependent kinase inhibitor 1 (p21) thereby inhibiting 
tumor growth in a xenograft model (Pelletier et al., 2011). These HIF-independent functions 
of FIH-1 underline that the characterisation of new substrates for the enzyme is of major 
importance. Beside Notch and IκB proteins, there are multiple protein families containing 
ARDs which are not characterised with respect to their potential to be hydroxylated by FIH-1 
to date, among these the family of apoptosis-stimulating p53-binding proteins (ASPPs). 
 
1.2 Apoptosis-stimulating p53-binding proteins (ASPPs) 
1.2.1 General characteristics 
The ASPP protein family consists of three members, ASPP1, ASPP2 and inhibitory ASPP 
(iASPP) and was initially found to modulate p53-dependent signalling pathways. The 
proapoptotic members ASPP1 and ASPP2 were shown to stimulate the proapoptotic function 
of p53 before iASPP was identified as an oncoprotein inhibiting p53-dependent apoptosis 
(Samuels-Lev et al., 2001; Bergamaschi et al., 2003). The three family members share a 
highly conserved C-terminus containing different protein-protein interaction domains, a 
proline-rich region, an ARD and a Src-homology 3 (SH3) domain. For two ASPPs, truncated 
forms were described before characterisation of the full length protein (Fig. 5). As a first 
member of the protein family, ASPP2 was identified. 
 
1.2.2 ASPP1 and ASPP2 
1.2.2.1 Structure, function and regulation 
Initially, a truncated form of ASPP2, termed p53-binding protein 2 (53BP2), was identified in 
a yeast two-hybrid screen as a protein interacting with the tumor suppressor p53 (Iwabuchi et 
al., 1994). 53BP2 comprises the 529 C-terminal amino acids of the full length protein 
containing the structural motifs important for protein interactions, the proline-rich region, the 
ARD and the SH3 domain (Fig. 5).  
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1 1090
ASPP1 SH3α-helical ARDProUbl
478 828
RAI SH3ARDPro
123 1128
Bbp SH3α-helical ARDPro
53BP2 SH3ARDPro
600 1128
1
ASPP2 SH3α-helical ARDProUbl
1128
1
iASPP SH3ARDPro
828
 
 
Fig. 5: Domain structure 
of apoptosis-stimulating 
p53 binding proteins 
(ASPPs). (A) Structure of 
the full length protein 
ASPP2, its splice variant 
Bcl-2 binding protein 
(Bbp) and the  
initially identified protein 
fragment p53 binding 
protein 2 (53BP2).  
(B) Structure of ASPP1.  
(C) Structure of full 
length inhibitory ASPP  
(iASPP) and the initially  
identified splice variant  
RelA-associated inhibitor 
(RAI). Ubl, ubiquitin-like 
fold; Pro, proline-rich 
region; ARD, ankyrin 
repeat domain; SH3,  
Src-homology 3 domain.  
 
 
The ARD-SH3 region not only mediates interaction with p53 but is also involved in binding 
of numerous other interaction partners of ASPP2 (Table 2). The interaction with B-cell 
lymphoma 2 (Bcl-2) led to the identification of the splice variant Bcl-2 binding protein (Bbp) 
comprising the 1005 C-terminal amino acids of ASPP2 in a yeast two-hybrid screen for 
proteins interacting with Bcl-2 (Naumovski and Cleary, 1996). Finally, the full length protein 
of 1128 amino acids was characterized together with the family member ASPP1 containing 
1090 amino acids (Fig. 5) (Samuels-Lev et al., 2001).  
Exogenous expression of ASPP1 and ASPP2 was shown to enhance the transactivation 
function of p53 on promoters of proapoptotic genes leading to an increased apoptotic response 
of the cells (Samuels-Lev et al., 2001). Recently, ASPP1 and ASPP2 were shown to induce 
p53-dependent apoptosis in vivo in retinal ganglion cells following optical nerve damage via 
induction of p53 upregulated modulator of apoptosis (PUMA) and Fas receptor (Wilson et al., 
2013). The redundant apoptosis-stimulating function of ASPP1 and ASPP2 not only applies 
to p53 itself but also to the p53 family members p63 and p73 which were shown to be 
regulated by ASPPs in a similar fashion concerning the transactivation of proapoptotic genes 
in vitro (Bergamaschi et al., 2004). 
 
B 
C 
A 
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Table 2: Protein interactions of ASPP2.  
Protein Function 
Interaction site 
of ASPP2 
Functional consequences of  
interaction 
Reference(s) 
p53 
apoptosis, cell cycle 
arrest, DNA repair 
ARD-SH3 
ASPP2: enhanced 
transactivation of proapoptotic 
genes 
C-terminus: dominant 
negative 
(Samuels-Lev et al., 
2001) 
p63 
apoptosis, cell cycle 
arrest 
not mapped 
enhanced transactivation of 
proapoptotic genes 
(Bergamaschi et al., 
2004) 
p73 
apoptosis, cell cycle 
arrest 
not mapped 
enhanced transactivation of 
proapoptotic genes 
(Bergamaschi et al., 
2004) 
Bcl-2 apoptosis inhibition ARD-SH3 --- 
(Naumovski and 
Cleary, 1996) 
PP1 
serine/threonine 
phosphatase 
ARD 
promotes dephosphorylation 
of TAZ by PP1 
(Helps et al., 1995; 
Liu et al., 2010a) 
p65 
(RelA) 
NF-κB subunit ARD-SH3 --- (Yang et al., 1999b) 
YAP 
development  
(Hippo pathway) 
SH3 --- 
(Espanel and Sudol, 
2001) 
APCL 
cytoskeletal 
regulation 
ARD-SH3 --- 
(Nakagawa et al., 
2000) 
APP-BP1 
cell cycle regulation 
(neddylation 
pathway) 
N-terminus  
(aa 332–483) and 
Pro-ARD-SH3 
inhibits cell proliferation and 
protects against  
APP-BP1-induced apoptosis 
(Chen et al., 2003) 
HCV core 
protein 
hepatitis C virus 
core protein 
ARD-SH3 --- (Cao et al., 2004) 
IRS-1 
insulin receptor 
substrate 
ARD-SH3 
inhibits insulin-induced 
tyrosine phosphorylation of 
IRS-1 
(Hakuno et al., 2007) 
DDA3 
mitotic spindle 
regulation 
N-terminus  
(aa 1–450) and 
ARD-SH3 
--- (Sun et al., 2008) 
DDX42 
ATP-dependent 
RNA helicase 
N-terminus  
(aa 415–489) and 
ARD-SH3 
--- 
(Uhlmann-Schiffler 
et al., 2009) 
p300 
acetyl transferase, 
transcriptional  
co-activator 
not mapped 
complex formation of  
ASPP2-p53-p300 enhances 
p53 transcriptional activity on 
proapoptotic genes 
(Gillotin and Lu, 
2011) 
CagA 
Helicobacter pylori 
effector protein, 
induces EMT 
not mapped 
inhibits p53 accumulation and 
transcriptional activity 
(Buti et al., 2011) 
Bcl-W apoptosis inhibition ARD-SH3 --- (Katz et al., 2008) 
Bcl-XL apoptosis inhibition ARD-SH3 --- (Katz et al., 2008) 
Par-3 
cell polarity, 
tight/adherens 
junction formation 
N-terminus 
(aa 2-353) 
necessary for epithelial cell 
polarity, controls neuronal 
progenitor proliferation and 
polarity 
(Cong et al., 2010; 
Sottocornola et al., 
2010) 
HRas 
GTPase, growth 
factor signalling 
N-terminus 
(aa 1-100) 
promotes membrane 
localisation, promotes  
Ras signalling 
(senescence/apoptosis) 
(Wang et al., 2013a; 
Wang et al., 2013b) 
EMT: epithelial to mesenchymal transition 
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Besides structural and functional similarities, ASPP1 and ASPP2 are also regulated by the 
same family of transcription factors in a similar fashion. E2F transcription factors which are 
critical for the control of cell cycle, proliferation and apoptosis were shown to bind the 
promoters of endogenous ASPP1 and ASPP2 and to upregulate the expression of both 
proteins (Chen et al., 2005; Fogal et al., 2005; Hershko et al., 2005). In breast cancer cell 
lines apoptosis induced by the chemotherapeutic agent resveratrol was found to depend on an 
E2F-1 mediated increase of ASPP1 emphasising the importance of this regulatory mechanism 
(Shi et al., 2011).  
 
1.2.2.2 Stimulation of p53-dependent apoptosis by ASPP1 and ASPP2 
The apoptosis-stimulating function is best characterised for ASPP2 although the precise 
mechanism has not been elucidated yet. The solution structure of the ARD-SH3 region of 
ASPP2 in complex with p53 revealed that the binding site for ASPP2 is located in the p53 
core domain and overlaps the DNA-binding domain (Gorina and Pavletich, 1996). Because of 
the overlapping binding sites the formation of a ternary complex of ASPP2, p53 and DNA 
seems unlikely and could indeed be excluded from competitive binding studies (Tidow et al., 
2006; Patel et al., 2008).  
Moreover, the predominantly cytoplasmic localisation of ASPP1 and ASPP2 argues against a 
direct effect on the transactivation function of p53 but rather suggests an indirect signal 
transduction pathway through which proapoptotic ASPPs trigger p53-dependent apoptosis. 
Supporting this hypothesis, several studies have shown that the ASPP2-mediated stimulation 
of apoptosis was decreased upon co-expression of other interaction partners which implies a 
competition for binding of different proteins to the ARD-SH3 region of ASPP2 (Cao et al., 
2004; Takahashi et al., 2005; Sun et al., 2008). 
Besides the highly conserved C-terminus responsible for the interaction with p53, ASPP1 and 
ASPP2 show a high sequence similarity in the N-terminal 100 amino acids which were shown 
to adopt a β-Grasp ubiquitin-like fold (Fig. 5) and to share some sequence homology with Rat 
sarcoma (Ras) association domain (RAD) containing proteins (Tidow et al., 2007). Very 
recently, the interaction of ASPP1 and ASPP2 with Ras via this domain was demonstrated to 
potentiate Ras signalling (Wang et al., 2013a). 
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Ras small GTPases are well-known oncogenes in human cancer as mutations rendering Ras 
permanently active occur frequently leading to uncontrolled proliferation of tumor cells via 
various cellular signalling pathways (Pylayeva-Gupta et al., 2011). In addition, Ras has also 
been demonstrated to possess the opposing function and induce apoptosis and senescence 
which can be mediated by p53-dependent signalling pathways (Spandidos et al., 2002; 
Overmeyer and Maltese, 2011). ASPP2 has previously been shown to act as a mediator of 
Ras-induced senescence via interaction between Ras and the N-terminus of ASPP2 (Wang et 
al., 2011; Wang et al., 2013b). Recently, it could be demonstrated that this interaction is also 
involved in the stimulation of p53-dependent apoptosis via ASPP1 and ASPP2 (Wang et al., 
2013a).  
 
1.2.2.3 Mouse models of ASPP1 and ASPP2 deficiency 
Consistent with the role of ASPP2 in the regulation of apoptosis via p53 family members, 
heterozygous mice are more susceptible to spontaneous tumor development compared to 
wild-type mice (Kampa et al., 2009). Moreover, the tumor suppressor function of ASPP2 in 
vivo was shown to require the presence of p53 as tumor development in mice was unaffected 
by ASPP2 gene dosage in the absence of p53 (Vives et al., 2006). The homozygous deletion 
of ASPP2 which revealed a new function of the protein in the regulation of cell polarity was 
carried out in another genetic background because all pups of the two mouse models 
mentioned above died before weaning. ASPP2 knockout mice showed a hydrocephalus and 
retinal dysplasia due to the loss of tight junction integrity at the choroid plexus and abnormal 
growth of neuroepithelial cells (Sottocornola et al., 2010). These defects could be connected 
to the disorganised localisation of components of the apical junctional complex (AJC) which 
is involved in the regulation of cell-cell adhesion, epithelial barrier function and cell polarity. 
The AJC is composed of tight and adherens junctions which are formed by protein 
subcomplexes (Martin-Belmonte and Perez-Moreno, 2011). One of these complexes 
responsible for the establishment of cell polarity is the Par complex consisting of the two 
scaffolding proteins partitioning defective 3 homolog (Par-3) and partitioning defective 6 
homolog (Par-6) and the atypical protein kinase C (aPKC). ASPP2 could be shown to form an 
alternative cell polarity complex with Par-3 in vivo whose disruption causes the defects in 
neuronal development observed in the ASPP2 knockout mice (Sottocornola et al., 2010). The 
interaction of ASPP2 and Par-3 could also be detected in vitro in human cancer cell lines and 
the cell-cell contact localisation was shown to be interdependent as depletion of one of the 
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interaction partners disrupted the junctional localisation of the other protein (Sottocornola et 
al., 2010). Interestingly, the Par-3-binding domain of ASPP2 is located within the N-terminus 
of the protein and does not comprise the ARD-SH3 domain which is responsible for binding 
of most of the interaction partners, including p53 (Table 2) (Cong et al., 2010). To date, it is 
unclear, whether the control of cell polarity and neuronal progenitor proliferation via ASPP2 
are p53-dependent because the combined knockout mice are embryonic lethal (Sottocornola et 
al., 2010).  
In contrast to the ASPP2 heterozygous mice, the phenotype of ASPP1 knockout mice was 
shown to be independent of p53 function. These mice manifest delayed lymphatic vessel 
assembly during embryogenesis. The mechanism involving ASPP1 in this developmental 
malfunction is not clarified to date (Hirashima et al., 2008).  
Taken together, the different mouse models demonstrate that, despite redundant functions in 
p53 regulation observed in vitro, ASPP1 and ASPP2 regulate different signalling pathways 
pointing to unique functions of each protein in vivo. This is supported by several studies 
reporting further p53-independent functions of the proteins in vitro (Aylon et al., 2010; Liu et 
al., 2010a; Vigneron et al., 2010). 
 
1.2.2.4 ASPP1 and ASPP2 - beyond p53 regulation 
Besides regulation of p53 function, ASPP1 was shown to affect the Hippo signalling pathway 
which controls cell proliferation and apoptosis independent of p53 (Aylon et al., 2010; 
Vigneron et al., 2010). The Hippo signalling pathway is essential for organ size control during 
mammalian development. The inhibition of cell proliferation and induction of apoptosis are 
mediated through the regulation of the transcriptional co-activators Yes associated protein 
(YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) which can associate 
with different transcription factors upon activation, e.g. members of the TEA domain (TEAD) 
family and the tumor suppressor p73 (Halder and Johnson, 2011). YAP and TAZ are inhibited 
by phosphorylation via a kinase cascade when the Hippo pathway is activated which leads to 
the inhibition of cell proliferation. ASPP1 has been shown to act on this pathway via two of 
these kinases, large tumor suppressor 1 and 2 (LATS1 and LATS2), which catalyse the 
phosphorylation of YAP and TAZ. On the one hand, ASPP1 can inhibit the kinase activity of 
LATS1 in the cytoplasm leading to the activation of YAP and TAZ (Vigneron et al., 2010). 
One consequence of the activation of YAP by ASPP1 is the downregulation of LATS2 which 
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reduces p53 transactivation function on the p21 promoter thereby inhibiting cell cycle arrest 
and senescence induction (Vigneron and Vousden, 2011). On the other hand, phosphorylation 
of ASPP1 by LATS2 can trigger the nuclear translocation of a LATS2/ASPP1 complex under 
oncogenic stress conditions which promotes apoptosis of polyploid cells in a p53-dependent 
manner (Aylon et al., 2010).  
ASPP2 has also been shown to be implicated in the activation of the Hippo pathway through 
enhanced dephosphorylation of TAZ which is catalysed by one of the ASPP2 interaction 
partners, protein phosphatase 1 (PP1) (Table 2) (Liu et al., 2010a). Moreover, a direct 
interaction of YAP and ASPP2 has been reported, but the biological relevance of this 
interaction is still unclear (Table 2) (Espanel and Sudol, 2001).  
As listed in Table 2, a multitude of other interaction partners were identified for ASPP2 with 
partially unknown function to date suggesting that the protein is involved in numerous other 
signalling pathways. As the biological relevance of most of these interactions could not be 
revealed yet, they will not be discussed further in detail. 
 
1.2.3 iASPP 
1.2.3.1 Structure, function and regulation 
Similar to the identification of ASPP2, a truncated iASPP form was first identified in a yeast 
two-hybrid screen. The C-terminal 351 amino acids of the full length protein were found to 
interact with the NF-κB subunit p65 (RelA) and to inhibit NF-κB-dependent gene expression 
(Yang et al., 1999a). Thus, the potential splice variant of iASPP was termed RelA-associated 
inhibitor (RAI) (Fig. 5). Full length iASPP was identified together with its C. elegans 
homolog ape-1 which were both found to inhibit apoptosis induced by p53 (Bergamaschi et 
al., 2003). In contrast to the full length protein, expression of the splice variant RAI could not 
be detected in several cancer cell lines suggesting that it is either restricted to certain tissues 
or represents a truncated version of iASPP not occurring in vivo (Slee et al., 2004). However, 
RAI has been shown to localise almost exclusively to the nucleus while iASPP is partially 
located to the cytoplasm which indicates that the N-terminus of the protein controls the 
subcellular localisation enabling iASPP-dependent signalling in both cellular compartments 
(Slee et al., 2004).  
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p53 REGDNA-binding domain TETProTAD L
* * *
1.2.3.2 Inhibition of p53-dependent apoptosis and cell cycle arrest by iASPP 
 
 
 
Fig. 6: Domain structure of p53. The tumor suppressor p53 consists of an N-terminal transactivation domain 
(TAD), a proline-rich region (Pro), a central core DNA-binding domain which is separated from the 
tetramerisation domain (TET) by a linker region (L). The C-terminus of p53 contains a regulatory domain 
(REG). ASPP interaction sites referred to in the text are indicated by asterisks. 
 
To date, little is known about the regulation of iASPP but it could be demonstrated that 
activation of NF-κB triggers the expression in hepatocellular carcinoma cells via a putative 
NF-κB binding site in the iASPP promoter (Lu et al., 2010).  
Initially, suppression of iASPP in human breast cancer and osteosarcoma cell lines was shown 
to stimulate apoptosis in a p53-dependent manner (Bergamaschi et al., 2003). This could be 
verified in other cancer cell lines of different origin, e.g. lung (Li et al., 2012) and 
hepatocellular carcinoma (Lu et al., 2010). Besides regulation of apoptosis, iASPP was also 
found to stimulate proliferation of cancer cells through inhibition of p53-dependent cell cycle 
arrest (Chen et al., 2010; Li et al., 2011). 
Moreover, increased chemosensitivity of cancer cells has been reported upon depletion of 
iASPP (Liu et al., 2009; Lu et al., 2010). These effects could also be confirmed in a xenograft 
mouse model with human hepatocellular carcinoma cells where upregulation of iASPP 
enhanced tumor growth and chemoresistance while suppression of the protein had the 
opposite effect (Lu et al., 2010). 
As for ASPP2, direct interaction of the iASPP ARD-SH3 region with the p53 DNA-binding 
domain could be detected in cancer cells (Bergamaschi et al., 2003) although subtle 
differences were observed in the binding interfaces. While ASPP2 preferentially binds to the 
core domain of p53, iASPP interacts with a linker region adjacent to the core (Fig. 6) (Ahn et 
al., 2009). Moreover, the interaction interfaces of ASPP2 and iASPP were found to differ in 
the charge of residues exposed to the surface of the proteins which might provide differences 
in protein interactions (Benyamini and Friedler, 2011). Although both proteins show a similar 
binding affinity for p53, iASPP was found to have a 3-fold higher affinity for the p53 family 
members p63 and p73 which were also shown to be regulated by iASPP (Robinson et al., 
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2008; Cai et al., 2012). Besides the DNA-binding domain, a second region for ASPP 
interaction located in the proline-rich region of p53 could be identified (Fig. 6). A common 
p53 polymorphism in this region at codon 72 (proline to arginine) decreases binding of iASPP 
to a greater extent than binding of ASPP2 confirming the differences in the interaction 
interfaces of the proteins (Bergamaschi et al., 2006). In addition to regulation of p53 activity, 
iASPP is also involved in p53-independent signalling pathways with a similar outcome 
triggering cellular proliferation on one hand and suppressing apoptotic responses on the other. 
 
1.2.3.3 iASPP knockout mouse model 
One example for p53-independent signalling of iASPP is derived from a knockout mouse 
model which identified iASPP as a key player in the regulation of epithelial stratification 
(Notari et al., 2011). iASPP was shown to regulate this process via inhibition of the 
transcriptional activity of p63 which acts as a master transcription factor in epithelial 
development. As in the case of ASPP1 and ASPP2, the knockout mouse model for iASPP 
highlights the importance of p53-independent functions of the protein. Indeed further 
signalling pathways mediated by iASPP where p53 is dispensable were identified in vitro.  
 
1.2.3.4 iASPP - beyond p53 regulation 
Several studies report that silencing of iASPP inhibits proliferation of cancer cells in a 
p53-independent manner. iASPP suppression in p53-defective prostate cancer cells inhibited 
growth, in vitro colony-forming capacity of the cells and even tumorigenesis in vivo due to an 
increase in apoptosis (Zhang et al., 2011). Moreover, a decreased expression of iASPP in 
p53-deficient bladder cancer cell lines has been reported to inhibit proliferation (Liu et al., 
2011). In ovarian cancer cell lines iASPP silencing increased not only paclitaxel-induced 
apoptosis but also mitotic catastrophe, i.e. an alternative cell death pathway, irrespective of 
the p53 status of the cells (Jiang et al., 2011). Furthermore, iASPP suppression in 
keratinocytes was shown to inhibit proliferation through induction of a differentiation 
pathway suggesting a role of iASPP in stem cell maintenance (Chikh et al., 2011). These 
effects might at least in part be associated to the modulation of p63 and p73, as iASPP has 
been shown to stimulate the activity of these transcription factors leading to the induction of 
proapoptotic proteins (Cai et al., 2012). Additionally, an interaction between iASPP and PP1 
which was previously shown to be bound by ASPP2 has been reported, although the 
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biological relevance of this interaction is unclear to date (Llanos et al., 2011). iASPP was also 
found to affect Ras signalling. In contrast to ASPP1 and ASPP2, iASPP functions as an 
oncoprotein in this context and enhances the transforming activity of Ras in a p53-dependent 
manner (Bergamaschi et al., 2003). Taken together, the studies suggest that iASPP is an 
interesting target in cancer therapy as suppression of the protein could induce an anti-
proliferative and proapoptotic program in cancer cells irrespective of the p53 status. 
 
1.2.4 ASPPs and cancer 
In line with ASPPs being involved in central cellular signalling pathways regulating cellular 
proliferation as well as apoptotic responses, alterations of ASPP expression levels and 
regulation have frequently been observed in human tumor tissues.  
Consistent with the in vitro studies revealing the oncogenic potential of iASPP, the expression 
levels of the protein were shown to be increased in vivo in a multitude of human tumor 
samples including breast cancer (Bergamaschi et al., 2003), prostate cancer (Zhang et al., 
2011), non-small cell lung cancer (Chen et al., 2010), glioblastoma (Li et al., 2011), acute 
leukemia (Zhang et al., 2005) and hepatocellular carcinoma (Lu et al., 2010). For ovarian 
cancer (Jiang et al., 2011), head and neck squamous cell carcinoma (HNSCC) (Liu et al., 
2012) and squamous cell cervical cancer (Cao et al., 2013) high iASPP expression levels were 
correlated with a poor prognosis for the patients or with chemoresistance of the cancer cells. 
One study even suggests an iASPP polymorphism (A67T) potentially predisposing smokers 
to lung cancer development (Deng et al., 2010). In summary, the elevated expression 
observed in a multitude of different cancer types demonstrates the potential of iASPP as 
prognostic tumor marker and a possible target for cancer treatment.  
In contrast to iASPP, the proapoptotic ASPP family members were frequently shown to be 
downregulated in tumor samples, e.g. in endometrial adenocarcinomas (Liu et al., 2010b). In 
non-small cell lung cancer samples the decrease of ASPP1 and ASPP2 mRNA was found to 
be even more pronounced in samples expressing wild-type p53 (Li et al., 2012). Reduced 
transcription of ASPP1 and ASPP2 could be shown to be mediated by aberrant DNA 
methylation in various p53 wild-type cancer cell lines (Liu et al., 2005) and in hepatitis B 
virus-positive hepatocellular carcinoma (Zhao et al., 2010). For ASPP1, inactivation by 
aberrant promoter methylation has also been described to correlate with poor prognosis or 
metastasis in acute lymphoblastic leukemia (Agirre et al., 2006) and non-small cell lung 
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cancer (Wei et al., 2011), respectively. Moreover, downregulation of ASPP1 has been 
reported in leukemia cell lines (Liu et al., 2004) and gestational trophoblastic disease (Mak et 
al., 2011). For ASPP2, decreased mRNA expression was found to correlate with poor 
prognosis in lymphoma (Lossos et al., 2002) and a frameshift mutation was detected in one 
gastric and two colorectal cancer samples with mircosatellite instability (Park et al., 2010). 
Moreover, a high expression of ASPP2 in cancer cells correlates with sensitivity to cisplatin 
and irradiation (Mori et al., 2000). Finally, the ASPP2-p53 interaction interface reveals that 
all the contact residues of p53 are frequently mutated in human cancers suggesting that the 
ASPP2-dependent stimulation of apoptosis might selectively be switched off in p53 wild-type 
cancer cells (Gorina and Pavletich, 1996).   
In summary these studies confirm the tumor suppressive roles of ASPP1 and ASPP2 on one 
hand and the oncogenic potential of iASPP on the other. In general, targeting the ASPP 
protein family may be a promising new approach in cancer therapy. For example, a 37 amino 
acid peptide derived from the DNA-binding domain of wild-type p53 was shown to stimulate 
cancer cell death irrespective of the p53 status by disruption of an iASPP-p73 complex 
releasing p73 from iASPP-mediated suppression which restores the proapoptotic function 
(Bell and Ryan, 2008). This approach provides an interesting new mechanism through which 
p53 wild-type and mutant tumors could be targeted in cancer therapy by inhibition of iASPP.    
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1.3 Aim of the study 
As demonstrated by recent findings, the members of the ASPP family are important for 
several cellular signalling pathways which affect tissue homeostasis and developmental 
processes as well as tumor development and progression. A database comparison revealed 
potential hydroxylation sites for FIH-1 in the ARD of all three members of the protein family. 
The scope of this study was to determine whether ASPPs are modified by FIH-1 at the 
posttranslational level, because hypoxic conditions are often encountered by the organism in 
development as well as in pathological processes such as tumor formation. As ASPPs are 
implicated in these processes, it was of great interest to determine whether ASPPs are 
hydroxylated by FIH-1 and consequently affected by insufficient oxygen supply.  
To date, the functional consequences of ARD hydroxylation could not be revealed. As ASPPs 
are involved in numerous signalling pathways and multiple protein interactions the 
hydroxylation of these proteins may be particularly suitable to study the impact of 
FIH-1-dependent ARD modification. The finding that FIH-1 suppresses the p53-p21 
signalling axis together with the potential hydroxylation site suggests that ASPPs are targeted 
by FIH-1 to modulate p53 signalling.  
Furthermore, a connection between intracellular oxygen-sensing mechanisms and  
ASPP-dependent signalling pathways could explain hypoxia-dependent effects on 
physiological processes which are not mediated by HIF on the transcriptional level. 
Consequently, we investigated whether ASPPs are targeted for hydroxylation by FIH-1 and 
examined the functional consequences of the protein modification.   
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2 Material and Methods 
2.1 Material 
2.1.1 Reagents and consumables  
Reagents and enzymes used in this study were all obtained in p.a. quality. Radiochemicals 
were from Perkin-Elmer (Waltham, Massachusetts, USA). Laboratory equipment and 
consumables not mentioned met laboratory standards.  
 
2.1.2 Technical devices  
Technical devices were from the companies listed in Table 3.  
 
Table 3: Technical devices used in this study 
Equipment Companies 
Laser scanning microscope 
Zeiss LSM510 
Carl Zeiss (Oberkochen, Germany) 
Fusion-FX7 chemiluminescence 
documentation system 
Peqlab (Erlangen, Germany) 
Tri-Carb2900R liquid 
scintillation counter 
Perkin-Elmer (Waltham, Massachusetts, USA) 
Hypoxic working chamber Toepffer Lab System (Göppingen, Germany) 
FLx800 fluorescence reader Biotek (Winooski, Vermont, USA) 
Epoch spectrophotometer Biotek (Winooski, Vermont, USA) 
Sequencing service LGC Genomics (Berlin, Germany); Microsynth (Balgach, Switzerland) 
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2.1.3 Buffers and media 
Media and buffers frequently used in this study are listed in Table 4. 
 
Table 4: Buffers and media 
PBS 138 mM 
8.1 mM 
2.7 mM 
1.5 mM 
Tris (pH 7.4) 
Na2HPO4 
KCl 
KH2PO4 
TBS 20 mM 
137 mM 
Tris (pH 7.4) 
NaCl 
Running buffer 
(SDS-PAGE) 
25 mM 
0.192 M 
0.1% (w/v) 
Tris (pH 7.4) 
glycine 
SDS 
Transfer buffer 
(Western blotting) 
25 mM 
0.192 M 
Tris (pH 7.4) 
glycine 
Stacking gel buffer (5%) 5% (w/v) 
125 mM 
0.1% (w/v) 
0.05% (w/v) 
0.1% (v/v) 
acrylamide 
Tris (pH 6.8)  
SDS 
APS 
TEMED 
Separating gel buffer 5 – 12.5% (w/v) 
375 mM 
0.1% (w/v) 
0.05% (w/v) 
0.05% (v/v) 
acrylamide 
Tris (pH 8.8) 
SDS 
APS 
TEMED 
SDS sample buffer 62.5 mM 
2% (w/v) 
3% (v/v) 
10% (v/v) 
0.25 mg/ml 
25 mM 
Tris (pH 7.4) 
SDS 
β-mercaptoethanol 
glycerol 
bromphenol blue 
DTT 
LB-medium (pH 7.0) 10 g/l 
5 g/l 
10 g/l 
tryptone 
yeast extract 
NaCl 
LB-agar 
 
15 g/l 
LB-medium (pH 7.0) 
agar 
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Cell culture media were obtained from Life Technologies (Darmstadt, Germany) and 
Promocell (Heidelberg, Germany) and supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin, 2 mM glutamine and 10% (v/v) FBS (Life Technologies, Darmstadt, Germany). 
Antibiotics used for plasmid selection are listed in Table 5. 
 
 
Table 5: Antibiotics used for plasmid selection 
Antibiotic Concentration 
ampicillin 100 µg/ml 
kanamycin 40 µg/ml 
chloramphenicol 50 µg/ml 
 
 
2.1.4 Bacterial strains and eukaryotic cell lines 
All bacterial strains and eukaryotic cell lines used in this study are listed in Table 6 and 7, 
respectively. 
 
 
Table 6: Bacterial strains 
Strain Characteristics Source/Reference 
XL1-blue competent 
E. coli 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F’ proABlaclqZΔM15 Tn10 (Tetr)] 
Agilent Technologies  (Santa 
Clara, California, USA) 
Cat. No.: 200228 
BL21-
CodonPlus(DE3)-
RIPL competent  
E. coli 
E. coli B F-ompThsdS(rB
-, mB
-) dcm+Tetrgalλ(DE3) 
endAHte [argUproLCamr] [argUileYleuW 
Strep/Specr] 
Agilent Technologies (Santa 
Clara, California, USA) 
Cat. No.: 230280 
One Shot Stbl3
TM
 
competent E. coli 
F-mcrBmrrhsdS20(rB
-, mB
-) recA13 supE44 ara-14 
galK2 lacY1 proA2 rpsL20(StrR) xyl-5 λ-leumtl-1; 
endA1+ 
Life Technologies 
(Darmstadt, Germany) 
Cat. No.: C7373-03 
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Table 7: Eukaryotic cell lines 
Eukaryotic cell line Origin Characteristics Medium Selection Source 
HCT116 
human 
colorectal 
carcinoma 
p53 wild-type McCoy’s 5A 
6 µg/ml 
puromycin 
Vogelstein, B. 
ATCC #CCL-247 
DLD-1 
human 
colorectal 
carcinoma 
p53 mutation 
DMEM high 
glucose 
2 µg/ml 
puromycin 
ATCC #CCL-221 
CaCo-2 
human 
colorectal 
carcinoma 
p53 truncation 
DMEM high 
glucose 
2 µg/ml 
puromycin 
ATCC #HTB-37 
H441 
human lung 
carcinoma 
p53 mutation RPMI 1640 
2 µg/ml 
puromycin 
ATCC #HTB-174 
HEK293T 
human 
embryonic 
kidney 
SV40 T-antigen 
DMEM high 
glucose 
2 µg/ml 
puromycin 
DSMZ #ACC-635 
 
2.1.5 Plasmids, shRNA sequences and PCR primers 
All shRNA sequences, plasmids and PCR primers used in this study are listed in Table 8, 9 
and 10, respectively. PCR primers were from Sigma (Munich, Germany) or Microsynth 
(Balgach, Switzerland). 
 
Table 8: shRNA sequences 
shRNA Sequence Reference 
shFIH-1 
GCCCTTGTTGAACACAATGAT corresponding to nucleotides 
1086-1106 of the FIH-1 mRNA (GenBank NM_017902) 
Sigma  
(Munich, Germany); 
TRCN0000064823 
shASPP2 
GCCTTTCTTATCTAATCCTTA corresponding to nucleotides 
2551-2571 of the ASPP2 mRNA (GenBank NM_005426) 
Sigma  
(Munich, Germany); 
TRCN0000061797 
shPar-3 
GCCATCGACAAATCTTATGAT corresponding to nucleotides 
3112-3132 of the Par-3 mRNA (GenBank NM_0019619) 
Sigma  
(Munich, Germany); 
TRCN0000118134 
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Table 9: Plasmids 
Plasmid Characteristics/Insert Reference 
pcDNA3.1/ASPP2-V5 
mammalian expression plasmid containing  
C-terminal V5-tagged human ASPP2 mRNA 
(GenBank: AJ318888) 
(Samuels-Lev et al., 2001) 
pET28a(+) FIH-1 
bacterial expression plasmid containing N-terminal 
His-tagged full length FIH-1 mRNA (NM_017902) 
(Hewitson et al., 2002) 
pcDNA3 FIH-1 
mammalian expression plasmid containing full 
length FIH-1 mRNA (NM_017902) 
(Metzen et al., 2003) 
pET32a HIF-1α 
bacterial expression plasmid coding for N-terminal 
His-tagged HIF-1α aa 737-826 
(Linke et al., 2004) 
pET32a HIF-1α N803A 
bacterial expression plasmid coding for N-terminal 
His-tagged HIF-1α aa 737-826 with a point 
mutation N803A 
(Linke et al., 2004) 
pMD2.G 
mammalian expression vector coding for lentiviral 
envelope gene products 
Addgene; #12259 
psPAX2 
mammalian expression vector coding for lentiviral 
packaging gene products 
Addgene; #12260 
pLKO.1-puro 
pLKO.1 control plasmid without shRNA sequence 
or stuffer 
Addgene; #10879 
pLKO.1 shscrambled 
pLKO.1 control plasmid containing scrambled 
shRNA sequence 
Addgene; #1864 
pGEX-4T-1 HIF-1α 
bacterial expression plasmid coding for N-terminal 
GST-tagged HIF-1α aa 737-826 
this study 
pGEX-4T-1 HIF-1α 
N803A 
bacterial expression plasmid coding for N-terminal 
GST-tagged HIF-1α aa 737-826 with a point 
mutation N803A 
this study 
pGEX-4T-1 ASPP2 
bacterial expression plasmid coding for N-terminal 
GST-tagged ASPP2 aa 852-1091 
this study 
pGEX-4T-1 ASPP2 N986A 
bacterial expression plasmid coding for N-terminal 
GST-tagged ASPP2 aa 852-1091 with a point 
mutation N986A 
this study 
pGEX-4T-1 ASPP2 N986T 
bacterial expression plasmid coding for N-terminal 
GST-tagged ASPP2 aa 852-1091 with a point 
mutation N986T 
this study 
pET24a(+) N-His ASPP2 
bacterial expression plasmid coding for N-terminal 
His-tagged ASPP2 aa 852-1091 
this study 
pET24a(+) N-His ASPP2 
N986A 
bacterial expression plasmid coding for N-terminal 
His-tagged ASPP2 aa 852-1091 with a point 
mutation N986A 
this study 
pET24a(+) N-His ASPP2 
N986T 
bacterial expression plasmid coding for N-terminal 
His-tagged ASPP2 aa 852-1091 with a point 
mutation N986T 
this study 
pET24a(+) N-His ASPP2 
N984T 
bacterial expression plasmid coding for N-terminal 
His-tagged ASPP2 aa 852-1091 with a point 
mutation N984T 
this study 
pET24a(+) N-His ASPP2 
N984T/N986T 
bacterial expression plasmid coding for N-terminal 
His-tagged ASPP2 aa 852-1091 with the point 
mutations N984T and N986T 
this study 
pET24a(+) C-His ASPP2 
bacterial expression plasmid coding for C-terminal 
His-tagged ASPP2 aa 852-1091 
this study 
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Table 10: PCR primers 
Primer Sequence 5’ 3’ Modification 
N-His ASPP2 F 
ATGGATCCCACCACCACCACCACCACAATCCAGAGGCTCCAC
ATGT 
BamHI site 
N-His ASPP2 R TAGAAGCTTTCAGTCTTCCCTGTGGATGATTG HindIII site 
C-His ASPP2 F ATGGATCCAATCCAGAGGCTCCACATGT BamHI site 
C-His ASPP2 R TAGAAGCTTGTCTTCCCTGTGGATGATTG HindIII site 
GST-ASPP2 F ATGGATCCAATCCAGAGGCTCCACATGT BamHI site 
GST-ASPP2 R TAGCTCGAGTCAGTCTTCCCTGTGGATGATTG XhoI site 
GST-HIF-1α F TAGGATCCTTATTACAGCAGCCAGACG BamHI site 
GST-HIF-1α R TTAGTCGACTCAGTTAACTTGATCCAAAGC SalI site 
ASPP2 N986A F CCTGGTACAGTTTGGTGTAAATGTAGCGGCTGCTGATAG 
point 
mutation 
ASPP2 N986A R GAGTCCATCCATCACTATCAGCAGCCGCTACATTTACAC 
point 
mutation 
ASPP2 N986T F CCTGGTACAGTTTGGTGTAAATGTAACCGCTGCTGATAG 
point 
mutation 
ASPP2 N986T R GAGTCCATCCATCACTATCAGCAGCGGTTACATTTACAC 
point 
mutation 
ASPP2 N984T F AAGTTCCTGGTACAGTTTGGTGTAACCGTAAATGCTGCT 
point 
mutation 
ASPP2 N984T R TCCATCACTATCAGCAGCATTTACGGTTACACCAAACTG 
point 
mutation 
ASPP2 
N984T/N986T F 
AAGTTCCTGGTACAGTTTGGTGTAACCGTAACCGCTGCT 
point 
mutation 
ASPP2 
N984T/N986T R 
TCCATCACTATCAGCAGCGGTTACGGTTACACCAAACTG 
point 
mutation 
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2.1.6 Antibodies 
The primary and secondary antibodies used in this study for immunodetection of proteins are 
listed in Table 11 and 12. 
 
Table 11: Primary antibodies 
Antigen MW Product number/clone Company 
ASPP2 170/150 kDa #611354/clone 19/53BP2 BD Biosciences (Heidelberg, Germany) 
Par-3 180/150/100 kDa #07-330 
Millipore (Billerica, Massachusetts, 
USA) 
HIF-1α 120 kDa #610959/clone 54/HIF-1α BD Biosciences (Heidelberg, Germany) 
β-actin 42 kDa #A2103 Sigma (Munich, Germany) 
GAPDH 36 kDa #G9545 Sigma (Munich, Germany) 
FIH-1 40 kDa #NB100-428 Novus Biologicals (Littleton, USA) 
p53 53 kDa #OP43/clone DO-1 Merck (Darmstadt, Germany) 
p53 53 kDa #04-1083/clone Y5 
Millipore (Billerica, Massachusetts, 
USA) 
p21 21 kDa #556431/ clone SXM30 BD Biosciences (Heidelberg, Germany) 
Bcl-2 26 kDa #sc-783/clone C21 
Santa Cruz Biotechnology (Dallas, 
Texas, USA) 
V5 --- #V8137 Sigma (Munich, Germany) 
MW: molecular weight 
 
Table 12: Secondary antibodies 
Conjugate Specificity Product number Company 
HRP mouse PO447 DAKO (Glostrup, Denmark) 
HRP rabbit PO448 DAKO (Glostrup, Denmark) 
Atto 647N mouse 50185 Sigma (Munich, Germany) 
Atto 647N rabbit 40839 Sigma (Munich, Germany) 
Alexa Fluor 488 mouse A-11017 Life Technologies (Darmstadt, Germany) 
Alexa Fluor 488 rabbit A-11070 Life Technologies (Darmstadt, Germany) 
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2.2 Methods 
2.2.1 Transformation of bacteria 
Heat shock transformation of competent bacteria listed in Table 6 was performed according to 
the instructions of the manufacturer. 
 
2.2.2 Preparation of plasmid DNA 
XL1-blue E. coli were used for general preparation of plasmid DNA. Preparation of DNA 
containing unstable inserts, e.g. lentiviral DNA containing direct repeats, was performed in 
One Shot Stbl3
TM
 E. coli. Isolation of plasmid DNA was carried out as recommended by the 
manufacturer using the plasmid purification kits from Qiagen (Hilden, Germany) for maxi, 
Promega (Madison, Wisconsin, USA) for midi and Thermo Fisher Scientific (Waltham, 
Massachusetts, USA) for mini preparations. 
 
2.2.3 Recombinant protein expression 
 
Table 13: Expression and storage conditions for recombinant proteins 
Protein Induction Temperature Expression time Storage 
His-HIF-1α 1 mM IPTG 37°C 4 h -80°C; 10% glycerol; stable 
His-FIH-1 1 mM IPTG 30°C 6 h -20°C; 50% glycerol; stable 
His-ASPP2 0.5 mM IPTG 20°C 16 h 4°C; unstable 
GST 1 mM IPTG 37°C 6 h -80°C; 10% glycerol; stable 
GST-HIF-1α 1 mM IPTG 30°C 6 h -80°C; 10% glycerol; stable 
GST-ASPP2 1 mM IPTG 30°C 6 h -80°C; 10% glycerol; stable 
 
 
Protein expression was performed in BL21-CodonPlus (DE3)-RIPL competent E. coli cells 
grown in LB-medium. First an overnight culture of the transformed bacteria was grown at 
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37°C and 220 rpm in 5 ml selection medium containing the corresponding antibiotic and 
chloramphenicol in the appropriate concentration (Table 5). Subsequently a larger culture of 
100-500 ml selection medium without chloramphenicol was inoculated from the overnight 
culture and protein expression induced at OD600 = 0.4-0.6 by addition of IPTG. Specific 
expression conditions for the different recombinant proteins are listed in Table 13. Following 
expression, cultures were collected by centrifugation, the supernatant discarded and cell 
pellets were either directly subjected to purification or stored at -20°C until purification. 
Storage conditions for recombinant proteins following purification are listed in Table 13. For 
analysis of protein expression culture samples taken before induction and after expression 
were prepared in SDS sample buffer and analysed by SDS-PAGE and subsequent Coomassie 
staining (staining buffer: 0.1% (w/v) Coomassie Brilliant Blue R-250, 45% (v/v) methanol, 
10% (v/v) acetic acid; destaining buffer: 10% (v/v) methanol, 10% (v/v) acetic acid). 
 
2.2.4 Polymerase Chain Reaction (PCR) 
2.2.4.1 Standard PCR 
Standard reactions for amplification of DNA fragments were performed in a mixture 
containing template plasmid DNA (20 pg/µl), primer oligonucleotides (forward and reverse, 
1 µM each), dNTP (200 µM each), DMSO (5% (v/v)) and Pfu- or Taq-Polymerase 
(0.05 U/µl). Buffers containing MgCl2 or MgSO4 were added as recommended by the 
manufacturer of the polymerases (Thermo Fisher Scientific, Waltham, Massachusetts, USA). 
Cycling conditions for standard PCR were: 1 x (3 min 95°C); 33 x (30 sec 95°C; 30 sec 58°C; 
30 sec – 3 min (depending on the length of the amplicon) 72°C ); 1 x (10 min 72°C). PCR 
reactions were performed in a TRIO thermal cycler (Biometra, Göttingen, Germany) and 
resulting PCR products were purified by gel extraction using the QIAEX II kit (Qiagen, 
Hilden, Germany) or the GeneJET gel extraction kit (Thermo Fisher Scientific).  
 
2.2.4.2 Overlap PCR for mutagenesis 
To generate amino acid exchanges in expressed proteins, the corresponding DNA sequences 
were mutated by means of overlap PCR (Ho et al., 1989). In addition to the external primers 
used for amplification of the whole template DNA, internal primers containing the appropriate 
base pair exchanges of about 35 bp length overlapping the mutation site about 10 bp in each 
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direction were used for two initial PCR reactions under standard conditions generating two 
fragments, one upstream (external forward, internal reverse primer) and one downstream 
(internal forward, external reverse primer) relative to the mutation site. Following purification 
of these fragments by gel extraction using the QIAEX II kit or the GeneJET gel extraction kit 
a new PCR reaction was performed with the external primers. Both fragments were used as 
template DNA in equimolar concentrations and standard PCR conditions were modified 
slightly decreasing the annealing temperature to 55°C.  
 
2.2.5 In vitro DNA recombination 
DNA restriction digestion and ligation reactions were carried out as recommended by the 
manufacturer of the enzymes, Thermo Fisher Scientific (Waltham, Massachusetts, USA). 
 
2.2.6 Agarose gel electrophoresis 
Agarose gel electrophoresis for analysis and purification of DNA was performed in 1 x TAE 
buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA) using the MINI GEL II system (VWR, 
Darmstadt, Germany). DNA was stained using the Sybr Green nucleic acid stain (Life 
Technologies, Darmstadt, Germany). For visualisation and documentation of DNA the 
Fusion-FX7 documentation system from Peqlab (Erlangen, Germany) was used. Purification 
of DNA fragments from agarose gels was conducted using the QIAEX II kit or the GeneJET 
gel extraction kit as recommended by the manufacturer. As a molecular weight standard the 
GeneRuler 1 kb DNA ladder from Thermo Fisher Scientific (Waltham, Massachusetts, USA) 
was used. 
 
2.2.7 Cell culture 
2.2.7.1  Culture conditions for eukaryotic cell lines 
Mammalian cell lines were cultured in a humidified incubator at 37°C under 5% CO2 and 
21% oxygen. For maintenance of adherent cultures, cells were trypsinised by incubation with 
0.25% trypsin/EDTA solution (Life Technologies, Darmstadt, Germany). Centrifugation steps 
were generally performed at room temperature for 3 min and 280 x g. Adherent cells were 
grown to a maximal confluence of 70-90%. For quantification, cells were counted either 
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manually using a counting chamber or automatically using the Cellometer Auto T4 from 
Peqlab (Erlangen, Germany). 
2.2.7.2  Cryopreservation of eukaryotic cell lines 
For cryopreservation, cells were resuspended in FBS containing 10% DMSO following 
centrifugation at 4°C for 3 min and 280 x g. Tubes with cells were immediately placed in an 
isopropanol-filled freezing jar and incubated overnight at -80°C. Subsequently cells were 
either stored for up to 6 months at -80°C or transferred into liquid nitrogen the next day. 
2.2.7.3  Transfection of cell cultures 
Transient transfections were performed using GeneJuice (Merck, Darmstadt, Germany) in a 
ratio of 3:1 (µl reagent:µg DNA) as recommended by the manufacturer. Alternatively, to 
maximise yield of the overexpressed protein, transient transfections were performed using 
TurboFect (Thermo Fisher Scientific, Waltham, Massachusetts, USA) in a ratio of 
2:1 (µl reagent:µg DNA) as recommended by the manufacturer. 
2.2.7.4  Lentivirus production in HEK293T cells 
Production of lentivirus was performed in HEK293T cells. 7.5-8 x 10
5
 cells were seeded in 
25 cm
2
 flasks. At a confluence of 50-70% (usually overnight incubation) cells were 
transfected as outlined above using GeneJuice. The transfection mixture contained three 
different plasmids necessary for virus production: 6 µg of the pLKO.1 vector expressing 
shRNA to suppress the target gene, 4 µg psPAX2, the packaging plasmid, and 2 µg pMD2.G, 
the envelope vector. Transfected cells were grown for 48-60 h and the supernatant containing 
the viral particles passed through a 0.45 µm filter for purification. The virus solution was 
either directly used or stored at -80°C in 2 ml aliquots until use for transduction. 
2.2.7.5  Lentiviral transduction of cell cultures 
For transduction, 2x10
5 
adherent cells were seeded in 25 cm
2
 flasks with 2x10
6
 transduction 
units in 2 ml DMEM and 8 µg/ml polybrene to support adherence of the viral particles to the 
cells. After 24 h incubation the virus solution was replaced by full growth medium. Following 
an expression period of 48 h cells were selected with a high concentration of puromycin for at 
least 3 days. The concentrations used for selection which were determined for each individual 
cell line by dose-response measurements, are listed in Table 7. Following selection, cells were 
maintained in normal culture medium in the absence of selection pressure. Stability of the 
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transient knockdown was monitored by Western blotting in parallel to the experiments 
performed. 
2.2.7.6  Irradiation, chemotherapeutic and hypoxic treatment of cell cultures 
For chemotherapeutic treatment and irradiation, adherent cells were grown to a confluence of 
50-60%. Before stimulation, growth medium was exchanged. After treatment cells were 
grown for the indicated time. Chemotherapeutic agents were applied for the whole incubation 
time. Irradiation was performed using an Isovolt 320 (Pantak-Seifert, East Haven, 
Connecticut, USA) running at 320 kV and 10 mA with a 1.65 aluminium filter. The effective 
photon energy was approximately 90 kV with a dose rate of about 2.76 Gy/min. For 
subsequent analysis, cells were lysed as indicated for the corresponding method. Hypoxic 
incubations were performed using a Hypoxic working chamber (Toepffer Lab System, 
Göppingen, Germany). Anoxic incubations were performed in the GasPak™ system (BD 
Biosciences, Heidelberg, Germany). 
2.2.7.7  Proliferation measurement 
To measure cell proliferation cells were seeded into 96-well plates at low density (2x10
3
 cells 
per well). After 1, 4 and 7 days of growth cells were incubated with 0.5 mg/ml thiazolyl blue 
tetrazolium bromide (MTT) for 2 - 4 h at 37°C and lysed with MTT lysis buffer (50% (v/v) 
N,N-dimethylformamide, 20% (w/v) SDS, 0.01% acetic acid, 0.01 M HCl) to solubilise 
formazan crystals. Following lysis absorbance was measured at 540 nm with 700 nm as 
reference wave length in an Epoch multimode reader (Biotek, Winooski, Vermont, USA). As 
a second assay for proliferation, cells were seeded into 6-well plates at low density and 
counted after 1, 4 and 7 days of growth using the Cellometer Auto T4. 
2.2.7.8  Scratch assay 
Cellular migration was measured by scratch assay. In brief, cells were grown to confluent 
monolayers in culture dishes coated with rat collagen-I (Biozol, Eching, Germany) before 
scratching. Closure of the introduced wounds was quantified as reduced distance between the 
edges over time. At the indicated time points images were taken using a Zeiss Axiovert 200 M 
microscope (Carl Zeiss, Oberkochen, Germany). Distances were measured at 11 different 
positions of each scratch for statistical analysis. Representative data from at least three 
independent experiments are shown. 
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2.2.7.9  Adhesion assay 
For quantification of cellular adhesion 4x10
4
 HCT116 or H441 cells were seeded into 
collagen-coated 96-well plates. Following an adhesion period of 2 h at 37°C in serum-free 
medium containing 0.5% BSA the plate was washed twice with PBS to remove floating cells. 
For fluorescent detection adherent cells were incubated with 2.5 µM calcein-AM and 
fluorescence quantified every 5 min at an excitation of 485 nm and emission wavelength of 
525 nm over 2 h in a FLx800 fluorescence reader. Replicate values (n = 10 per experiment) of 
a single time point in the linear range of the reaction were plotted for analysis of the results. 
2.2.7.10 Pulse-chase labelling of cellular proteins 
For pulse-chase labelling of cellular proteins with 
35
S-methionine, HCT116 cells were starved 
with medium lacking methionine for 15 min. Labelling of the cellular proteins was achieved 
by incubation with EasyTag™ L-[35S]-Methionine (NEG709A) (Perkin-Elmer) at a dose of  
7 µCu per cm
2
 adherent cell culture for 40 min. Subsequently, residual 
35
S-methionine was 
removed by washing with PBS and the cells were incubated with medium containing  
non-labelled methionine for different time points to monitor degradation of the protein of 
interest. For generation of total cell extracts the culture dishes were chilled to 4°C, the culture 
medium removed and cells washed with PBS. Subsequently the cells were lysed in 1 ml  
NP-40 buffer (50 mM Tris pH 7.5; 150 mM NaCl; 0.5% NP-40; 2 mM EDTA) containing 
protease inhibitor cocktail (Roche, Mannheim, Germany) per 21 cm
2
 culture dish. For 
immunoprecipitation 900 µl cell lysate were incubated with the indicated antibody for 2 h at 
4°C and immune complexes were recovered by incubation with protein G sepharose beads 
(Sigma, Munich, Germany) for 1 h at 4°C. The beads were washed 10 times with at least 
20 volumes NP-40 buffer, resuspended in SDS sample buffer and boiled for 7.5 min at 95°C. 
After removal of the beads by centrifugation, the supernatant was analysed by SDS-PAGE. 
As a control for labelling, 1 µl of the crude cell lysate was boiled with SDS sample buffer for 
7.5 min at 95°C and subjected to SDS PAGE. The gel was fixed in TCA solution  
(10% (v/v) TCA; 10% (v/v) acetic acid; 30% (v/v) ethanol) and, following amplification of 
the signal by incubation in 1 M sodium salicylate, dried using a MGD-4534 gel dryer (VWR, 
Darmstadt, Germany). Radioactively labelled proteins were visualised by autoradiography. 
Representative data from two independent experiments are shown.  
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2.2.8 Purification of recombinant proteins 
2.2.8.1 Nickel affinity purification 
Cell pellets derived from bacterial protein expression were lysed in 20 mM Tris-HCL (pH 8), 
150 mM NaCl containing 1 x CelLytic
TM
 B (Sigma, Munich, Germany), 0.2 mg/ml lysozyme 
and protease inhibitor cocktail (Roche, Mannheim, Germany). Lysates were cleared by 
centrifugation and the salt concentration of the cleared lysate was increased to 500 mM NaCl. 
After addition of 5 mM imidazole, 0.5 mM DTT and 1 mM PMSF lysates were incubated 
with Ni-NTA Agarose (Qiagen, Hilden, Germany) at 4°C for 1 h. Before addition of the 
lysate, the agarose was prepared by 4 washing steps with 4 volumes of washing buffer 
(20 mM Tris-HCL (pH 8), 500 mM NaCl, 10 mM imidazole). After incubation with the 
lysate, the agarose was washed twice with 10 volumes washing buffer and bound protein 
eluted with 20 mM Tris-HCL (pH 8), 500 mM NaCl, 250 mM imidazole. After affinity 
purification protein solutions were directly desalted using PD-10 columns (GE Healthcare, 
Munich, Germany) and concentrated using the appropriate Amicon centrifugal filter device 
(Millipore, Billerica, Massachusetts, USA). Protein concentrations were measured at 280 nm 
and the purity of the proteins was estimated on Coomassie-stained SDS-PAGE gels. 
Depending on the stability, purified proteins were stored at -20 to -80°C in 10-50% glycerol 
(Table 13). 
 
2.2.8.2 Glutathione affinity purification 
For glutathione affinity purification cell pellets of bacterial cultures expressing the protein of 
interest were lysed in PBS containing 1 x CelLytic
TM
 B, 0.2 mg/ml lysozyme and protease 
inhibitor cocktail. Lysates were cleared by centrifugation and incubated with glutathione 
sepharose 4B (GE Healthcare, Munich, Germany) at 4°C for 1 h. Before addition of the 
lysate, sepharose was prepared by four washing steps with 4 volumes of PBS. After 
incubation with the lysate, the sepharose was washed twice with 10 volumes PBS and bound 
protein eluted with a 20 mM Tris-HCL buffer (pH 8.8) containing 150 mM NaCl and 25 mM 
reduced Glutathione. After affinity purification protein solutions were directly desalted using 
PD-10 columns and concentrated using the appropriate Amicon centrifugal filter device. 
Protein concentrations were measured at 280 nm and the purity of the proteins was estimated 
on Coomassie-stained SDS-PAGE gels. Depending on the stability, purified proteins were 
stored at -20 to -80°C in 10-50% glycerol (Table 13). 
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2.2.9 In vitro transcription and translation of proteins 
In vitro transcription and translation was performed directly before use of the protein 
according to the manufacturers instructions using rabbit reticulocyte lysate (L1170; Promega, 
Madison, Wisconsin, USA). For radioactive labelling of generated proteins EasyTag™ 
L-[
35
S]-Methionine (NEG709A) was added to the reaction as recommended by the 
manufacturer. In vitro transcription and translation of FIH-1 was conducted using the 
expression plasmid pET28a(+) FIH-1. 
 
2.2.10 Hydroxylase activity assay 
FIH-1 activity was quantified via the hydroxylation-coupled decarboxylation of 
2-oxo[1-
14
C]glutarate (NEC597) (Perkin-Elmer). Ca(OH)2 soaked filter papers were placed in 
the top of the sample tubes leading to the precipitation of 
14
C-labelled 
14
CO2 released from the 
reactions. Hydroxylation was assessed in a final volume of 40 µl containing 7.5 µM  
His-FIH-1, 10-300 µM substrate, 0.3% (w/v) BSA (3 mg/ml); 50 mM Tris-HCL (pH 7);  
0.5 mM DTT; 4 mM ascorbate; 20 µM FeSO4; 40 µM 2-oxo[1-
14
C]glutarate. After reaction at 
37°C for the indicated time-period the filter paper was dried and subjected to scintillation 
counting using Ultima Gold XR (Perkin-Elmer, Waltham, Massachusetts, USA) in a  
Tri-Carb2900R liquid scintillation counter (Perkin-Elmer). Peptides for hydroxylase activity 
assays were from Thermo Fisher Scientific (Waltham, Massachusetts, USA). Representative 
data from at least three independent experiments are shown. 
 
2.2.11 Sample preparation for mass spectrometry (MS) analysis  
Samples for MS analysis were prepared from HEK293T cells transiently transfected with 
pcDNA3.1/ASPP2-V5 for 24 h using TurboFect. Cells were lysed in RIPA lysis buffer 
(50 mM Tris pH 7.5, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium desoxycholate, 
2 mM EDTA) containing protease inhibitor cocktail. 1 mg protein of the cell extract was 
subjected to immunoprecipitation of ASPP2 using 10 µg specific antibody. 
Immunoprecipitates were separated on a reducing 5% SDS gel which was stained by colloidal 
Coomassie staining. First, the gel was fixed in 50% (v/v) methanol, 2% (v/v) phosphoric acid 
for 30 min. Following three washing steps with distilled water, the gel was incubated in 
35% (v/v) methanol, 2% (v/v) phosphoric acid, 17% (w/v) ammoniumsulfate for 1 h. Staining 
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was performed overnight after addition of 0.1% (w/v) Coomassie Brilliant Blue 250 G. 
Destaining was carried out in distilled water as required for visualisation of the bands. 
Subsequently bands were excised and subjected to LC-MS/MS analysis. 
 
2.2.12 LC-MS/MS analysis 
LC-MS/MS analyses were performed in cooperation by Dr. Katja Kuhlmann at the Medical-
Proteome Center at the Ruhr-University Bochum. The analysis was performed as previously 
described (Janke et al., 2013). In brief, excised protein bands, were destained by alternating 
incubation with 10 mM NH4HCO3 and 5 mM NH4HCO3/50% acetonitrile (ACN) (v/v) for 
10 min each, three times. Following reduction with 10 mM DTT for 45 min at 56°C, proteins 
were alkylated with 55 mM iodoacetamide for 30 min at room temperature in the dark. For  
in-gel digestion, bands were incubated overnight with 150 ng chymotrypsin (Promega, 
Madison, Wisconsin, USA) each in 10 mM ammonium bicarbonate. Subsequently, peptides 
were extracted twice from the gel by addition of 15 µl 0.05 TFA/50% ACN (v/v). ACN was 
removed from the combined extracts in vacuo. Peptide separation was performed using an 
Ultimate 3000 RSLCnano HPLC system (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) online-coupled to a QExactive mass spectrometer (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). The Mascot search engine (Matrix Science) was used to search MS/MS 
spectra against the Uniprot complete proteome set for homo sapiens (26.10.2012, 68.109 
entries) with a precursor tolerance of 5 ppm, a fragment tolerance of 20 mmu, chymotrypsin 
specificity with three missed cleavages allowed, cysteine-carbamidomethylation as fixed 
modification and oxidation of methionine and hydroxylation of asparagine as variable 
modifications. Peptide identifications were filtered by the peptide validator algorithm of 
ProteomeDisvoverer 1.3 at 1% false discovery rate on peptide level. MS/MS spectra for 
ASPP2 hydroxylated or non-hydroxylated peptides were inspected manually in addition to 
database searching. Elution profile areas from extracted ion chromatograms (5 ppm mass 
tolerance) of the respective masses were calculated in XCalibur (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) for quantitative comparison of peptides. Representative data 
from three independent experiments are shown.  
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2.2.13 In vitro protein interaction 
For detection of in vitro interaction with FIH-1, non-labelled recombinant substrates were 
treated as for the decarboxylation assay, except usage of 20 µM ZnAc instead of FeSO4 and 
40 µM NOG instead of radioactively labelled 2-OG. Following incubation with 10 µl in vitro 
transcribed and translated 
35
S-labelled FIH-1 at 37°C for 2 h, 50 µl Glutathione Sepharose 4B, 
prepared by three washing steps in at least 10 volumes of 50 mM Tris-HCl pH 7, were added 
to the samples and the final volume adjusted to 1 ml with 50 mM Tris-HCl pH 7. After 
incubation for 1 h at 4°C the beads were washed 4 times with 50 mM Tris pH 7, resuspended 
in SDS sample buffer and boiled for 7.5 min at 95°C. After removal of the beads by 
centrifugation, the supernatant was split up for analysis either by reducing SDS-PAGE and 
autoradiography to detect labelled proteins or by SDS-PAGE and Coomassie staining 
(see 2.2.3) to detect non-labelled proteins, respectively. Representative data from three 
independent experiments are shown. 
 
2.2.14 Determination of protein concentration 
The protein concentration of cell extracts was measured spectrophotometrically at 562 nm 
using the bicinchoninic acid (BCA) Protein Assay kit from Thermo Fisher Scientific 
(Waltham, Massachusetts, USA) as recommended by the manufacturer. Bovine serum 
albumin (BSA) was used as standard. 
 
2.2.15 Immnunoprecipitation of protein complexes 
To perform co-immunoprecipitation experiments cells were lysed in NP-40 lysis buffer 
(2.2.7.10) containing protease inhibitor cocktail for generation of whole cell extracts. 
Following incubation of a defined protein amount of the cell lysates with the indicated 
antibodies for 2 h at 4°C co-immunoprecipitation was performed by incubation with  
protein G sepharose beads for 1 h at 4°C. The beads were washed 10 times with at least 
20 volumes NP-40 buffer, resuspended in SDS sample buffer and boiled for 7.5 min at 95°C. 
After removal of the beads by centrifugation, the supernatant was analysed by SDS-PAGE 
and immunoblotting. For crosslinking of the protein complexes prior to immunoprecipitation 
cells were incubated with DSP (dithiobis[succinimidylpropionate]) (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) at a final concentration of 2 mM for 30 min at room 
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temperature. The reaction was stopped by incubation with 20 mM glycine (pH 7.5) for 30 min 
and following two washing steps with PBS, cells were lysed and whole cell lysates subjected 
to immmunoprecipitation as described above.   
 
2.2.16 SDS polyacrylamide gel electrophoresis (PAGE) and Western blotting 
For Western blotting whole cell extracts were prepared in RIPA lysis buffer (2.2.11) 
containing protease inhibitor cocktail. Defined protein amounts (25 µg – 50 µg) were 
prepared in SDS sample buffer and boiled for 7.5 min at 95°C. Proteins were separated using 
reducing 7.5 – 10% SDS gels and transferred onto PVDF membranes. Unspecific binding 
sites on the membranes were blocked by incubation in TBST (TBS, 0.1% Tween 20) 
containing 5% skimmed milk. Incubation steps with primary and HRP-conjugated secondary 
antibodies were performed as recommended by the manufacturer (Table 11 and 12). Detection 
of the HRP-conjugated secondary antibodies was conducted with an ECL kit (GE Healthcare, 
Munich, Germany) using the FX7 chemoluminescence documentation system. Representative 
data from at least three independent experiments are shown. 
 
2.2.17 Caspase-3 activity assay 
Cleavage of the caspase-3-specific substrate sequence DEVD from acetyl Asp-Glu-Val-Asp 
7-amido-4-methylcoumarin (Ac-DEVD-Amc, Sigma, A1086), resulting in the release of the 
fluorescent 7-amino-4-methylcoumarin (Amc), was quantified as an indicator of apoptosis. 
Cells were treated as indicated and lysed in NP-40-buffer (50 mM Tris pH 7.3, 150 mM NaCl, 
1% (v/v) NP-40) containing protease inhibitor cocktail. 50 µg of the cell lysates were 
incubated with a final concentration of 50 µM Ac-DEVD-Amc in caspase substrate buffer 
(50 mM HEPES pH 7.3, 100 mM NaCl, 10% (w/v) sucrose, 0.1% (w/v) CHAPS  
(3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate), 10 mM DTT) at 
37°C. For quantification of caspase activity fluorescence was measured every 10 min at an 
excitation of 360 nm and emission wavelength of 460 nm over 4 h in a FLx800 fluorescence 
reader. For analysis of the result values of a single time point in the linear range of the 
reaction were plotted. Representative data from three independent experiments are shown. 
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2.2.18 Immunofluorescence microscopy 
For immunofluorescence staining cells were grown to confluence on glass plates coated with 
rat collagen-I. Cells were washed once with PBS, fixed with 4% paraformaldehyde in PBS for 
30 min and permeabilised with 0.5% Triton X-100 in PBS for 3 minutes. Afterwards, 
unspecific binding sites were blocked with blocking buffer (2% BSA in PBS) for 15 min and 
incubated with primary antibodies in blocking buffer for 2 hours. Following 2 washing steps 
with blocking buffer, cells were incubated with Alexa Fluor 488 and Atto 647-conjugated 
secondary antibodies in blocking buffer for 1 h. Cells were washed twice with PBS, 
counterstained with 50 µg/µl DAPI (4′,6-diamidino-2-phenylindole), washed another three 
times with PBS and mounted using DAKO mounting medium (DAKO, Glostrup, Denmark). 
Slides were analysed using a Zeiss LSM510 confocal microscope with a 63x/1.2 NA oil 
immersion lens (Carl Zeiss, Oberkochen, Germany). Representative data from at least three 
independent experiments are shown. 
 
2.2.19 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5 software. Statistical significance 
between two groups was tested by Students t-test. Comparisons of more than two groups were 
performed by one-way ANOVA analysis. 
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3 Results 
3.1 Sequence similarities between ASPPs and known FIH-1 substrates 
Previous reports identified several ARD-containing proteins as substrates for FIH-1 
(chapter 1.1.4.2, Table 1). As the high conservation of the ARD suggested further unknown 
substrates, we compared the previously identified FIH-1 hydroxylation sites to obtain a 
consensus motif for hydroxylation by the enzyme suitable for a database search for new  
FIH-1 substrates. An alignment of the protein sequences comprising 20 upstream and 19 
downstream amino acids relative to the hydroxylation site revealed the consensus sequence 
“AAXXXXXXXXXXLLXXGADVNAXDXXGXXPLHXAXXXXXX” indicating residues 
which are conserved in at least 50% of the sequences (X meaning any residue). The consensus 
for the FIH-1 hydroxylation site did not change upon addition of substrates identified while 
our study was in progress (Fig. 7).  
The motif revealed that only 16 out of the 40 residues aligned are conserved among 50% of 
the sequences which demonstrates very low substrate specificity for the enzyme. Confirming 
the high variation in the hydroxylation site tolerated by FIH-1 none of the amino acid residues 
in the alignment was found 100% conserved among all substrates currently known. Even the 
hydroxylated amino acid can vary as the enzyme was recently found to hydroxylate aspartate 
and histidine residues as well if these are positioned appropriately in the ARD of the substrate 
(Yang et al., 2011a; Yang et al., 2011b).  
The consensus sequence perfectly matches the human ARD consensus. Thus, it was not 
surprising that a database search for similar protein sequences resulted in matches with 
several ARD-containing proteins. Besides significant similarities in the previously identified 
FIH-1 substrates we found the consensus sequences matching a number of other proteins, 
including all members of the ASPP protein family. The matching values for ASPPs were in 
part even higher than for some of the experimentally confirmed FIH-1 substrates strongly 
suggesting hydroxylation of ASPPs at the sites retrieved from the database search: 
ASPP1 N948, ASPP2 N986 and iASPP N687.  
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Fig. 7: Alignment of FIH-1 substrates previously identified. Alignment of protein sequences currently known 
to be hydroxylated by FIH-1. Conservation of the residues is indicated by differential colouring ranging from red 
for highly conserved amino acids over yellow, green and light-blue to dark-blue for less conserved residues. The 
consensus sequence shows amino acids which are at least 50% conserved among all sequences. Residues 
showing less than 50% conservation in the consensus sequences are marked with X. Alignment was created 
using the CLC Bio sequence viewer 6. The FIH-1 hydroxylation site is indicated by an asterisk.   
* 
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Fig. 8: Alignments of ASPPs and the FIH-1 substrate consensus sequence. Putative hydroxylation sites of 
ASPP family members aligned with the consensus sequence containing amino acids conserved in 50% of all 
FIH-1 substrates. Residues showing less than 50% conservation in the consensus sequence are marked with X. 
Alignment was created using the CLC Bio sequence viewer 6. The putative FIH-1 hydroxylation sites are 
indicated by asterisks.   
 
Alignments of these putative hydroxylation sites of ASPPs with the FIH-1 substrate 
consensus sequence revealed a high homology with slight differences between the family 
members. For ASPP2 and iASPP 12 of the 16 specified amino acids of the 50% consensus 
were identical while ASPP1 even showed 13 identities (Fig. 8).  
Importantly, a leucine residue 8 amino acids upstream of the potential target asparagine is 
conserved among all ASPPs. This residue was found to be the most conserved in the vicinity 
of the FIH-1 hydroxylation site among all substrates (Fig. 7) and it was previously shown to 
be important for interaction with the enzyme (Linke et al., 2007).  
The sequence alignments of ASPPs and the FIH-1 substrate consensus not only revealed 
putative hydroxylation sites but also demonstrated a higher conservation level between the 
proapoptotic ASPPs as compared to iASPP. An alignment of the putative FIH-1 sites of all 
ASPP family members shows that only five amino acids in the immediate vicinity of the 
potential target asparagine (positions -20 to +19) differ between ASPP1 and ASPP2 while 
iASPP showed a substantially higher degree of variation as compared to the proapoptotic 
ASPPs (Fig. 9).  
 
 
 
Fig. 9: Alignment of putative FIH-1 hydroxylation sites in ASPPs. Protein sequence alignment of the putative 
hydroxylation sites, ASPP1 N948, ASPP2 N986 and iASPP N687. Residues conserved in all sequences are 
coloured in red. Amino acids conserved among ASPP1 and ASPP2 are coloured in green and residues that differ 
in all sequences are shown in blue. Alignment was created using the CLC Bio sequence viewer 6. The putative 
FIH-1 hydroxylation site is indicated by an asterisk.   
* 
* 
* 
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These differences imply a differential regulation of pro- and antiapoptotic family members. 
Therefore it is interesting to determine whether both groups can be targeted by FIH-1 or 
whether hydroxylation is restricted to distinct ASPPs. 
 
 
3.2 FIH-1-dependent hydroxylation of ASPPs in vitro 
3.2.1 ASPP2 derived FIH-1 substrates 
As ASPP2 showed a high similarity with the FIH-1 consensus sequence and is involved in a 
variety of signalling pathways we decided to perform our initial experiments with this ASPP 
family member. First, we wanted to determine whether ASPP2 can serve as a substrate for 
FIH-1 in vitro. Therefore, we used a hydroxylase activity assay where enzyme activity can be 
quantified via decarboxylation of the 
14
C-labelled co-substrate 2-OG leading to the release of 
14
CO2 which can be precipitated as an indicator of hydroxylase activity (Linke et al., 2007).  
The in vitro hydroxylation reaction was performed using enzyme and substrate regions 
purified from a bacterial expression system. As positive and negative controls His-tagged 
HIF-1α fragments (His-HIF-1α) of nearly 100 amino acid length (aa 737-826) containing or 
lacking the FIH-1 hydroxylation site (Linke et al., 2004) were used (Fig. 10). To obtain 
similar protein fragments for ASPP2, amino acids 852-1091 were cloned into the bacterial 
expression plasmid pET24a(+) with an N-terminal His-tag by PCR (Fig. 10). Alternatively, 
the His-tag was positioned at the C-terminus by PCR cloning.  The ASPP2 test substrate was 
designed to contain approximately 100 amino acids up- and downstream of the putative FIH-1 
hydroxylation site to achieve the least artificial conditions possible and to enable proper 
folding of the ARD containing the target asparagine. As the enzyme was also purified via a 
His-tag, all substrates including HIF-1α were also cloned into pGEX-4T-1 by PCR for 
bacterial expression of N-terminal GST-tagged proteins (Fig. 10). These fusion proteins were 
not used in the hydroxylase activity assay because the large GST-tag was expected to interfere 
with the reaction. However, the GST-tag also allowed potential studies of enzyme-substrate 
interaction by in vitro pull-down assays. 
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Fig. 10: ASPP2 and HIF-1α sequences used for in vitro hydroxylase activity assessment and interaction 
assays. The sequences are shown as positioned in the full length protein. N-terminal protein tags are indicated. 
His, histidine-tag; GST, GST-tag; Ubl, ubiquitin-like fold; Pro, proline-rich region; ARD, ankyrin repeat 
domain; SH3, Src-homology 3 domain; bHLH, basic-helix-loop-helix domain; PAS, Per-Arnt-Sim domain;    
ODD,  oxygen-dependent degradation domain; NTAD, N-terminal transactivation domain; CTAD, C-terminal 
transactivation domain. 
 
 
3.2.2 Protein expression and purification 
For hydroxylase activity measurements, His-tagged full length FIH-1 (Hewitson et al., 2002) 
and substrate proteins were expressed in BL21 (DE3) E. coli cultures and purified from 
lysates by nickel affinity purification (Fig. 11). As assessed on Coomassie-stained  
SDS-PAGE gels by quantification using ImageJ, purity of the proteins was approximately 
95% for His-HIF-1α and 98% for His-ASPP2 fragments. For FIH-1, purity was more variable 
ranging from 65% to 85% in different enzyme preparations. The enzyme was stable over 
several months upon storage in 50% glycerol at -20°C, as well as the His-HIF-1α substrates 
which were stored in 10% glycerol at -80°C. In contrast, the His-ASPP2 substrates were 
unstable upon storage and therefore freshly prepared prior to each hydroxylase activity assay.    
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Fig. 11: Expression and purification of His-
FIH-1, His-HIF-1α, N-His- and C-His-ASPP2. 
Expression of the indicated His-tagged substrates 
(His-HIF-1α aa 737-826 (A), N/C-His-ASPP2 
aa 852-1091 (B)) and full length FIH-1 (C) was 
induced by IPTG in BL21 (DE3) E. coli cultures 
grown in LB medium. The recombinant proteins 
were purified from lysates by nickel affinity 
purification. Lysates of the non-induced (control) 
and induced (IPTG) culture were separated by 
SDS-PAGE and visualised by Coomassie staining 
together with the indicated amount of purified 
protein. For FIH-1 two exemplary enzyme 
preparations are shown. 
     
 
  
3.2.3 FIH-1-dependent hydroxylation of ASPP2 in vitro 
The hydroxylase activity assay was established using the well-characterised His-HIF-1α 
substrate containing the whole CTAD with the FIH-1 hydroxylation site N803 (aa 737-826) 
(Linke et al., 2004). The reaction, monitored via release of 
14
CO2 by scintillation counting, 
was found to be linear over more than 2 h (Fig. 12). To warrant maximal sensitivity for the 
following experiments on ASPP hydroxylation, the 2 h time point was chosen for subsequent 
analyses. Comparing the activity of FIH-1 on N- and C-terminal His-tagged ASPP2 test 
substrates at this time point to that of His-HIF-1α, we detected lower values for both  
His-ASPP2 substrates, but as compared to the negative control, His-HIF-1α where the 
hydroxylation site is substituted by alanine (N803A), values were significantly higher 
(Fig. 13 A).  
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Fig. 12: Time course of FIH-1-dependent hydroxylation 
of His-HIF-1α. 50 µM His-HIF-1α was incubated with 
7.5 µM His-FIH-1 in the presence of co-factors at 37°C. 
FIH-1 activity was quantified via release of 14CO2 from the 
reaction by scintillation counting. Hydroxylation of  
His-HIF-1α by FIH-1 was monitored over a period of 3 h. 
Triplicate values for each time point normalised to control 
samples lacking the enzyme are plotted. 
 
 
 
This is important because 2-oxoglutarate-dependent dioxygenases can also catalyse 
decarboxylation of the co-substrate in the absence of the primary substrate which is termed 
uncoupled activity (Koivunen et al., 2004). In line with previous reports on other  
ARD-containing FIH-1 substrates (Cockman et al., 2009b), the FIH-1-dependent 
hydroxylation of His-ASPP2 in vitro was less efficient as compared to His-HIF-1α containing 
the hydroxylation site (Fig. 13 A). Because the FIH-1 activity on His-ASPP2 was found to be 
higher with an N-terminal position of the His-tag, the N-His-ASPP2 substrate was used in 
mutation studies to identify the hydroxylated amino acid. First, the putative FIH-1 
hydroxylation site identified in our database search, N986, was mutated to alanine or in a 
more structure conserving way to threonine by overlap PCR.  
 
     A                 B 
 
 
 
 
 
 
 
 
 
 
Fig. 13: ASPP2 is hydroxylated by FIH-1 in vitro. (A) FIH-1 activity on N- and C-terminal His-tagged ASPP2 
test substrates as compared to His-HIF-1α wild-type and hydroxylation deficient (N803A) substrates used as 
positive and negative control, respectively. Activities are shown relative to His-HIF-1α. (B) FIH-1 activity on  
N-terminal His-ASPP2 substrate fragments containing (wt) and lacking (N986A) the putative FIH-1 
hydroxylation site. Activities are shown relative to His-ASPP2 wt. (A, B) 50 µM substrate was incubated with 
7.5 µM FIH-1 in the presence of co-factors at 37°C for 2 h. Enzyme activity was monitored via release of 14CO2 
from the reaction by scintillation counting. Triplicate values for each test substrate normalised to control samples 
lacking the enzyme are plotted. Significance was tested by one-way ANOVA (A) or Student’s t-test (B) where  
* indicates p < 0.05 and ** indicates p < 0.01. 
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Comparing the N986A mutant to wild-type His-ASPP2 in the hydroxylase activity assay 
showed that the mutation indeed reduced, but not completely abrogated enzyme turnover 
(Fig. 13 B). As still almost 50% of the activity was detected, the presence of another 
hydroxylation site was examined for the test substrate. Indeed, the protein sequence of ASPP2 
showed another asparagine two amino acids upstream of N986 (Fig. 9) which might be 
targeted by FIH-1 as well considering the low substrate specificity of the enzyme.  
To test whether hydroxylation of N984 occurs, we generated a threonine single mutant for this 
residue (N984T) and a threonine mutant lacking both asparagines (N984T/N986T). All 
mutants were expressed in BL21 (DE3) E. coli cultures and purified from culture lysates by 
nickel affinity purification yielding a similar degree of purity ranging from 87% to 94% as 
assessed on Coomassie-stained SDS-PAGE gels (Fig. 14). 
 
 
 
 
Fig. 14: Expression 
and purification of 
His-ASPP2 asparagine 
mutants. The indicated 
mutations were inserted 
into the expression 
plasmids by overlap 
PCR. Protein expression 
of the indicated  
N-terminal His-tagged 
ASPP2 test substrates 
was induced by IPTG in 
BL21 (DE3) E. coli. The 
recombinant proteins 
were purified from 
lysates by nickel affinity 
purification. Lysates  
of the non-induced 
(control) and induced 
(IPTG) culture were 
separated by SDS-
PAGE and visualised  
by Coomassie staining 
together with 2.5 µg of 
the purified protein.  
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Fig. 15: FIH-1-dependent hydroxylation of His-ASPP2 
asparagine mutants. The indicated N-terminal His-tagged 
ASPP2 test substrates in wild-type (wt) and mutant forms 
as indicated were incubated at a concentration of 50 µM 
with 7.5 µM FIH-1 in the presence of co-factors at 37°C for 
2 h. Enzyme activity was monitored via release of 14CO2 
from the reaction by scintillation counting. Activities are 
shown relative to His-ASPP2 wt. Six-fold values for each 
mutant normalised to control samples lacking the enzyme 
are plotted. Significance between each mutant and wt was 
tested by one-way ANOVA where * indicates p < 0.05 and  
** indicates p < 0.01. 
 
Subjecting the mutants to the hydroxylase activity assay, we observed similar effects of 
alanine and threonine mutation. Both mutations of N986 reduced hydroxylation significantly 
and to the same extent, but the residual FIH-1 activity observed for this substrate preparation 
was even higher than observed in the proceeding experiment with 75% of the wild-type 
activity detected (Fig. 15). The slightly more pronounced decrease observed for the double 
mutant was not significant in comparison to the N986 single mutants demonstrating that the 
high background was not due to hydroxylation of N984 instead of N986. In line with this, the 
single mutant for N984 did not show significant differences as compared to the wild-type 
substrate. However, the high background could still be caused by another hydroxylation site 
present in the test substrate. On the other hand, as the His-ASPP2 proteins were found to be 
unstable in solution, degradation products or precipitates might interfere with the 
hydroxylation reaction. To obtain a system with lower background for the analyses we 
designed short peptides of ASPP2 and also iASPP for further in vitro studies on the 
hydroxylation of ASPPs.  
 
3.2.4 ASPP peptide design  
The ASPP peptides were designed according to previous studies on the hydroxylation of 
peptides by FIH-1. All the peptides previously reported to be hydroxylated by FIH-1 
contained 20 amino acids comprising a relatively long region upstream to the hydroxylation 
site while only 3 to 5 downstream amino acids where included, e.g. aa 788-807 for HIF-1α 
(Cockman et al., 2006). As this region also includes the most conserved residues of our 
consensus sequence, among which is the previously discussed leucine residue at the 
-8 position (chapter 3.1, Fig. 7), we designed our peptides based on this study containing 15 
amino acids upstream of the target asparagine and 4 downstream residues (Fig. 16 A and B). 
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Fig. 16: ASPP peptide design. (A) Diagram showing the domain structure of ASPP2 and iASPP. Peptides 
designed for hydroxylase activity measurements are shown according to their position in the full length protein. 
(B, C) Protein sequence alignment of the ASPP2 peptide with the corresponding peptide for iASPP (B) and 
ASPP1 (C). Identical residues are coloured in red and different amino acids are shown in green. Putative FIH-1 
hydroxylation sites are indicated by asterisks. Ubl, ubiquitin-like fold; Pro, proline-rich region; ARD, ankyrin 
repeat domain; SH3, Src-homology 3 domain. 
 
 
Because ASPP1 shows a very high homology to the ASPP2 peptide with only 4 out of 20 
amino acids differing in non-conserved regions of the FIH-1 substrate consensus, the ASPP2 
peptide was tested as a representative of both proapoptotic ASPPs (Fig. 16 C). In contrast, 
iASPP showed substantially more variation with 10 different residues. Thus ASPP2 and 
iASPP peptides were generated in wild-type and mutant forms where the putative FIH-1 
hydroxylation sites were substituted by alanine (ASPP2 N986A, iASPP N687A). 
 
 
* 
* 
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3.2.5 FIH-1-dependent hydroxylation of ASPP peptides in vitro 
Subjecting the peptides for ASPP2 containing (wt) or lacking (N986A) the potential 
hydroxylation site to the hydroxylase activity assay we observed that mutation of N986 
almost completely abrogated enzyme turnover confirming the previous finding that N986 is a 
single hydroxylation site in this region of the protein (Fig. 17 A). Moreover, increasing 
concentrations of wild-type but not mutant peptide specifically enhanced the activity of FIH-1 
(Fig. 17 B). Comparing iASPP peptides containing (wt) or lacking (N687A) the potential 
hydroxylation site to ASPP2 peptides revealed that, in contrast to ASPP2, iASPP cannot serve 
as substrate for FIH-1 in vitro. Even increasing concentrations of the iASPP wild-type peptide 
up to 300 µM did not produce FIH-1 activity significantly exceeding background levels as 
determined by the use of the corresponding mutant (Fig. 17 C). Because the background 
activity we detected for the ASPP2 peptides was substantially lower than observed for the 
substrate protein fragments, the peptides were used to further characterise the hydroxylation 
of ASPP2 catalysed by FIH-1. 
 
A         B 
 
 
 
 
 
 
 
C Fig. 17: ASPP2 is hydroxylated by FIH-1 while 
iASPP is not modified by the enzyme. (A, B) 
FIH-1 activity on wild-type (wt) and mutant 
(N986A) ASPP2 peptides. (C) FIH-1 activity on 
wild-type (wt) and mutant ASPP2 (N986A) and 
iASPP (N687A) peptides. (A, C) Activities are 
shown relative to His-ASPP2 wt. If not indicated 
otherwise, peptides were incubated with 7.5 µM 
FIH-1 at a concentration of 50 µM in the presence 
of co-factors at 37°C for 2 h. Enzyme activity was 
monitored via release of 14CO2 from the reaction 
by scintillation counting. Triplicate (B, C) or  
four-fold (A) values for each sample normalised to 
control samples lacking the enzyme are plotted. 
Significance was tested by Student’s t-test with 
*** indicating p < 0.001. 
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We determined the Km value for the wild-type ASPP2 peptide to be 75 µM, which was 
comparable to those reported for other ARD-containing FIH-1 substrates identified so far 
(Fig. 18 A) (Wilkins et al., 2009). The 2-OG competitor NOG specifically blocked enzyme 
turnover in a concentration-dependent manner for wild-type but not for mutant ASPP2 
peptides (Fig. 18 B) which again demonstrates the specificity of the reaction. In summary, the 
in vitro data identify N986 as a single hydroxylation site in ASPP2. Although high 
background was detected in hydroxylase activity assays upon mutation of N986 using longer 
protein fragments, we did not identify other target amino acids for FIH-1. 
 
 
      A      B 
 
 
 
 
 
Fig. 18: Kinetics and specificity of FIH-1-dependent hydroxylation of ASPP2. (A) To determine the Km 
value for the ASPP2 wild-type (wt) peptide increasing concentrations of the peptide were incubated with 7.5 µM  
FIH-1 in the presence of co-factors at 37°C for 2 h. (B) Competitive inhibition of FIH-1 activity on ASPP2  
wild-type (wt) but not mutant (N986A) peptide. Peptides were incubated with 7.5 µM FIH-1 at a concentration 
of 50 µM in the presence of co-factors and the indicated concentration of the competitive inhibitor NOG at 37°C 
for 2 h. Enzyme activity was monitored via release of 14CO2 by scintillation counting. Triplicate values for each 
sample normalised to control samples lacking the enzyme are plotted. 
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3.3 FIH-1 dependent hydroxylation of ASPP2 in cells 
To directly verify hydroxylation in cells, ASPP2 purified from HEK293T cells was analysed 
by LC-MS/MS. To this purpose, full length ASPP2 was transiently overexpressed in the cells 
for 24 h and purified from cell lysates by immunoprecipitation. The purified proteins were 
separated by SDS-PAGE. To generate peptides containing N986, protein bands displaying the 
correct molecular weight were excised and subjected to digestion by proteases.  
Using chymotrypsin a peptide comprising the potential hydroxylation site N986 
(GVNVNAADSDGWTPL, [M+2H]
2+
=758.36) could reproducibly be detected. In addition to 
the signal at m/z 758.36, a signal with a mass difference of +16 ([M+2H]
2+
=766.36) 
corresponding to the hydroxylated peptide was observed at a slightly earlier retention time. 
The signal intensity in the MS survey scan for both peptides at the respective peak in the 
elution profile (Fig. 19 A) shows, that in HEK293T cells with endogenous FIH-1 expression, 
the protein was detected in the hydroxylated and in the unmodified form, with a higher 
intensity for the hydroxylated species. 
In order to show that the modification is indeed introduced by FIH-1, ASPP2 purified from 
cells containing different amounts of the active enzyme was analysed (Fig. 19 A and B).  
FIH-1 overexpression increased the relative amount of hydroxylation significantly, with the 
unmodified form close to the detection limit. In contrast, treatment with the hydroxylase 
inhibitor DMOG led to an increase of the unmodified variant with the hydroxylated species 
being barely detectable. Similarly, suppression of endogenous FIH-1 expression through 
lentiviral transduction of shRNA (shFIH-1) reduced the relative amount of hydroxylated 
protein. Although the FIH-1 knockdown was found to decrease hydroxylation less effectively 
as compared to the hydroxylase inhibitor, the reduction clearly demonstrated that ASPP2 
hydroxylation is mediated by FIH-1. Residual hydroxylation probably results from an 
incomplete knockdown. The efficiency was nearly 90%, with still 10% of the active enzyme 
present in the cells used for the analysis (Fig. 19 B). 
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Fig. 19: ASPP2 hydroxylation is detectable in cells and depends on FIH-1 activity and abundance. 
Chymotrypsin cleavage yielded the ASPP2 peptide GVNVNAADSDGWTPL which was detectable in a 
hydroxylated and a non-modified variant by LC-MS/MS analysis using overexpressed ASPP2 purified from 
HEK293T cells expressing endogenous FIH-1, cells transduced with shRNA against FIH-1 (shFIH-1), FIH-1 
overexpressing cells or cells treated with the hydroxylase inhibitor DMOG. (A) MS spectra from an LC-MS/MS 
analysis of ASPP2 purified from cells with different amounts or activity of FIH-1. The spectra are shown for the 
respective peak in the extracted ion chromatograms of the peptide variants (unmodified: [M+2H]2+=758.36, 
hydroxylated: [M+2H]2+=766.36). (B) Relative amounts of unmodified peptide in comparison to the 
hydroxylated peptide. Peak areas from extracted ion chromatograms (XIC) for the respective masses are shown. 
As control for overexpression and suppression of FIH-1 equal amounts of total cell lysates were subjected to 
SDS-PAGE and subsequent Western blotting (right panel). GAPDH was used as a loading control.  
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In addition, MS/MS analysis was performed to confirm the identity of the peptides detected 
(Fig. 20). The results showed a positive identification by the Mascot search engine with a 
false discovery rate of 1% and a Mascot score above 40. The b-ions which define N986 as the 
site of FIH-1-dependent hydroxylation are visible in the MS/MS spectrum. In summary, the 
results demonstrated that hydroxylation of ASPP2 at N986 occurs in cells and the amount of 
hydroxylation is correlated to FIH-1 activity and abundance. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20: N986 is the FIH-1 hydroxylation site in the ARD of ASPP2. Chymotrypsin cleavage yielded the 
ASPP2 peptide GVNVNAADSDGWTPL which was detectable in a non-modified (upper spectrum) and a 
hydroxylated (lower spectrum) variant by LC-MS/MS analysis using overexpressed ASPP2 purified from 
HEK293T cells. MS/MS spectra confirm the peptide identity demonstrating N986 as the site of modification. 
The mass shift of +16 Da and the hydroxylation site are highlighted in red. 
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3.4 FIH-1-ASPP2 interaction in vitro 
As hydroxylation of ASPP2 by FIH-1 also occurs in cells we wanted to further characterise 
the enzyme-substrate interaction in an in vitro approach. To perform pull-down assays we 
generated the same substrate proteins used for the hydroxylation studies with an N-terminal 
GST-tag (chapter 3.2.1, Fig. 10) as these were expected to interact with the enzyme. The 
substrates were expressed in BL21 (DE3) E. coli and purified from lysates by glutathione 
affinity purification. As assessed on Coomassie-stained SDS-PAGE gels purity of the proteins 
was approximately 98% for the GST control and 90% for GST-HIF-1α wild-type and the 
N803A mutant (Fig. 21 A and B).  
 
    A                        B        
 
 
 
 
 
    C 
 
 
 
 
 
Fig. 21: Expression and purification of GST, GST-HIF-1α and GST-ASPP2. Expression of GST alone (A) 
and the indicated GST-tagged proteins (GST-HIF-1α aa 737-826 (B), GST-ASPP2 aa 852-1091 (C)) was 
induced by IPTG in BL21 (DE3) E. coli grown in LB medium. The recombinant proteins were purified from 
lysates by glutathione affinity purification. Lysates of the non-induced (control) and induced (IPTG) cultures 
were separated by SDS-PAGE and visualised by Coomassie staining together with 2.5 µg of the purified protein.  
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For GST-ASPP2 proteins including wild-type and the two hydroxylation site mutants, N986A 
and N986T, purification was less efficient with about 60% purity achieved (Fig. 21 C). To test 
interaction with the enzyme the GST fusion proteins or GST alone were incubated with 
radioactively labelled FIH-1 with the substitution of 2-OG and Fe(II) by NOG and zinc to 
prevent hydroxylation and release of the substrates which generates trapped enzyme-substrate 
complexes (Elkins et al., 2003). 
Upon GST pull-down of the substrates, a substantially higher amount of FIH-1  
co-precipitated with GST-ASPP2 as compared to GST-HIF-1α while GST alone did not 
produce any signal (Fig. 22). Mutation of the GST-ASPP2 hydroxylation site N986 to alanine 
or threonine reduced interaction between enzyme and substrate substantially to the same 
extent. A similar effect could be observed for GST-HIF-1α following mutation of the 
hydroxylation site N803 to alanine. As less FIH-1 co-precipitated with GST-HIF-1α the 
mutation almost completely abrogated interaction while both GST-ASPP2 mutants were still 
able to bind a relatively high amount of the enzyme. Taken together these results demonstrate 
a strong interaction between ASPP2 and FIH-1 in vitro.  
 
 
 
 
 
 
 
 
Fig. 22: Interaction of FIH-1 and ASPP2 in vitro. Recombinant GST fusion proteins in wild-type (wt) and 
mutant forms as indicated were incubated at a concentration of 5 µM with equal amounts of 35S-methionine-
labelled FIH-1 generated by in vitro transcription and translation. To prevent hydroxylation and release of the 
substrate, 2-OG and Fe(II) were substituted by NOG and zinc producing a trapped enzyme-substrate complex. 
Following incubation the reactions were subjected to GST pull-down, bound proteins separated by SDS-PAGE 
and visualised by autoradiography to detect FIH-1 (upper panel) or by Coomassie staining for GST fusion 
proteins (lower panel).  
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3.5  Impact of FIH-1-dependent hydroxylation of ASPP2 
3.5.1 FIH-1 and ASPP2 co-localise in cells 
Next, we wanted to explore the physiologic consequences of this interaction and the 
hydroxylation of ASPP2 by FIH-1. As a prerequisite for studies on the consequences of  
FIH-1-dependent hydroxylation of ASPP2, the intracellular localisation of both proteins was 
analysed by immunofluorescence staining. ASPP2 was almost exclusively located to the cell-
cell contacts and cytoplasm of all human cancer cell lines examined. FIH-1 was shown to co-
localise with ASPP2 in the cytoplasm of HCT116 colon cancer cells (Fig. 23). As ASPP2 was 
shown to modulate p53-dependent signalling pathways, this p53 wild-type cell line, which 
was also available in an isogenic p53-deficient form, was found most suitable to study the 
impact of hydroxylation on ASPP2-mediated modulation of p53 activity.  
 
 
 
 
 
Fig. 23: Localisation of endogenous ASPP2 and FIH-1. Double immunofluorescence staining for endogenous 
ASPP2 (green) and FIH-1 (red) in untreated HCT116 cells. Nuclei were counterstained with DAPI.  
 
 
3.5.2 ASPP2 protein stability 
For further analysis of physiologic effects of ASPP2 hydroxylation by FIH-1 shFIH-1 cell 
lines were compared to control cells either transduced with an unspecific shRNA 
(shscrambled) or the empty vector pLKO.1. The knockdown efficiency for FIH-1 was found 
to be constantly higher than 80% (Fig. 24) for at least three weeks on the protein level. ASPP2 
protein levels were examined using HCT116 cells following suppression of FIH-1 through 
shRNA transduction or exposure to hypoxic or anoxic conditions. In HCT116 cells (Fig. 24) 
as well as in other cell lines (e.g. MCF-7, H441) we found no changes in ASPP2 protein 
levels following depletion of FIH-1.  
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Fig. 24: ASPP2 protein levels are not affected by silencing of FIH-1. HCT116 cells were transduced with 
shRNA against FIH-1 (shFIH-1) or empty vector (control) and exposed to normoxic (20% O2), hypoxic (1% O2) 
and anoxic (0.1% O2) conditions. Total cell lysates were produced after 4 h (A) or 24 h (B), equal protein 
amounts subjected to SDS-PAGE and subsequent Western blotting. β-actin served as a loading control. 
 
In addition, we detected similar amounts of the protein under hypoxic and anoxic conditions 
in control and shFIH-1 cells at different time points, indicating that ASPP2 is not regulated by 
FIH-1-dependent hydroxylation on the protein level. Similar results were obtained for the 
well-characterised FIH-1 substrate HIF-1α which was induced by hypoxic or anoxic 
conditions to the same extent, irrespective of the FIH-1 status of the cells. Although these 
results argue against a regulation of protein stability by enzymatic hydroxylation, ASPP2 has 
previously been reported to be regulated on the protein level by the 26S proteasome with a 
half-life of 60 to 80 minutes and almost complete degradation following 3 h of treatment with 
the translation inhibitor cycloheximide (Zhu et al., 2005). As alterations in the half-life of a 
protein are not necessarily associated with a change in overall protein levels (Kuhar, 2010), it 
is still possible that FIH-1-dependent hydroxylation of ASPP2 affects protein turnover. 
Therefore, we tried to determine the half-life of ASPP2 in HCT116 cells by two different 
methods. First, the translation inhibitor cycloheximide was applied in the absence and 
presence of the 26S proteasome inhibitor MG132 to monitor the proteasomal degradation of 
endogenous (Fig. 25 A) or exogenously expressed ASPP2 (Fig. 25 B). In the second 
approach, the pulse-chase technique was used to assess the degradation of overexpressed 
ASPP2 (Fig. 25 C).  
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Fig. 25: ASPP2 is not regulated by proteasomal degradation in HCT116 cells. (A, B) HCT116 cells 
expressing endogenous ASPP2 (A) or transiently transfected with V5-ASPP2 for 18 h (B) were incubated with 
100 µg/ml cycloheximide (CHX) with and without pretreatment with the proteasome inhibitor MG132 for 2 h at 
25 µM. Total cell lysates were produced at the indicated time points and equal protein amounts subjected to 
SDS-PAGE and subsequent Western blotting. As control for treatments the proteasomal regulation of p53 was 
monitored. β-actin served as a loading control. (C) HCT116 cells transiently transfected with V5-ASPP2 for 18 h 
were starved in methionine-free medium for 15 min. Subsequently, cells were incubated with 35S-labelled 
methionine for 40 min. The medium was exchanged to normal growth medium. Cells lysates were produced at 
the indicated time points and subjected to immunoprecipitation of V5-ASPP2 with 6 µg V5 antibody. 
Immunoprecipitates were separated by SDS-PAGE and visualised by subsequent autoradiography. The specific 
band for V5-ASPP2 is indicated by an asterisk.  
 
For this purpose, following starvation in medium lacking methionine, transfected cells were 
incubated with 
35
S-methionine for 40 min to achieve a defined pool of labelled protein. 
Subsequently, degradation of the protein pool was allowed for different periods in normal 
growth medium.  Both approaches did not lead to consistent results. First, we did not detect 
proteasomal regulation of ASPP2 in HCT116 cells as similar protein levels were detected in 
the absence and presence of the 26S proteasome inhibitor MG132 while the control protein, 
p53, was potently induced by the treatment. Although a decrease could be observed at 2 h to 
8 h after treatment with cycloheximide alone, the protein levels for endogenous ASPP2 were 
found to be comparable before (0 h) and 24 h after treatment while the control protein was 
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almost completely degraded confirming the efficacy of the treatment (Fig. 25 A). Similarly, 
proteasomal regulation could not be detected for exogenous ASPP2 expressed in HCT116 
cells transiently transfected with V5-ASPP2. Half of the protein was degraded irrespective of 
the addition of MG132 4 h to 6 h after treatment with cycloheximide (Fig. 25 B). These 
results were confirmed by pulse-chase experiments (Fig. 25 C).  
However, exogenous expression of V5-ASPP2 was found to induce apoptosis in HCT116 
cells as early as 24 h after transfection and the additional treatments necessary for half-life 
determination, i.e. cycloheximide addition or starvation and labelling increased the apoptotic 
response even further. Therefore, the decrease in protein levels could not directly be attributed 
to proteasomal degradation which precludes a clear statement on the half-life of ASPP2 and 
the impact of FIH-1-dependent hydroxylation in this context.    
 
3.5.3 Cell proliferation 
As ASPP2 was reported to regulate p53, protein levels of the tumor suppressor and 
proapoptotic as well as antiapoptotic targets of p53 were examined. This revealed an 
induction of p53 and the cell cycle inhibitor p21 upon suppression of FIH-1 in HCT116 cells 
(Fig. 26) while expression of proapoptotic targets was not affected. Because this increase in 
p53 and p21 was expected to affect proliferation and apoptosis of the cancer cells we 
examined if these processes were altered in shFIH-1 cells. Proliferation of the cells was not 
altered upon suppression of FIH-1 as quantified by MTT measurements in HCT116 
(Fig. 27 A) and H441 (Fig. 27 B) cells. These results were confirmed by cell counting 
experiments (data not shown). 
 
 
Fig. 26: FIH-1 silencing induces p53 and p21. 
HCT116 cells were transduced with shRNA 
against FIH-1 (shFIH-1) or empty vector (control) 
and exposed to normoxic (20% O2), hypoxic (1% 
O2) and anoxic (0.1% O2) conditions. Total cell 
lysates were produced after 24 h, equal protein 
amounts subjected to SDS-PAGE and subsequent 
Western blotting. β-actin served as a loading 
control. 
 
 
 61 
 
3 Results 
da
y 
1
da
y 
4
da
y 
7
0.0
0.5
1.0
1.5
control
shFIH-1
P
ro
li
fe
ra
ti
o
n
 O
D
 5
4
0
 n
m
da
y 
1
da
y 
4
da
y 
7
0.0
0.2
0.4
0.6
0.8
control
shFIH-1
P
ro
li
fe
ra
ti
o
n
 O
D
 5
4
0
 n
m
HCT116 H441
 A       B 
 
 
 
 
 
 
 
Fig. 27: FIH-1 depletion does not influence cellular proliferation in HCT116 and H441 cells. HCT116 (A) 
and H441 (B) cells were transduced with shRNA against FIH-1 (shFIH-1) or empty vector (control), seeded at 
low density and grown for the indicated periods. Following incubation with MTT, cells were lysed and 
proliferation was quantified by absorbance measurements at 540 nm. 
 
3.5.4 Apoptosis 
Apoptosis was induced by stimulation of HCT116 cells with chemotherapeutic drugs 
(etoposide or doxorubicin) for 48 h. Alternatively, apoptosis was analysed 72 h after ionizing 
radiation. The apoptotic response was quantified via the activity of the effector caspase-3 
using a substrate which becomes fluorescent upon cleavage. FIH-1-dependent differences in 
the apoptotic response to chemotherapy or irradiation were not detected although all 
treatments increased caspase-3 activity significantly, from 1.5 fold for irradiation with 5 Gray 
to 4.5 fold for doxorubicin treatment (Fig. 28 A and B).  
p53 was significantly induced following stimulation with doxorubicin and etoposide while 
p21 protein levels were decreased especially in response to doxorubicin treatment. 
Remarkably, we found an induction of ASPP2 on the protein level following doxorubicin 
treatment suggesting that ASPP2 shifts p53-dependent transactivation function from p21 to 
proapoptotic promoters.  
However, this was not dependent on the presence of FIH-1 as no differences in apoptosis 
induction were detectable in control and shFIH-1 cells upon chemotherapy (Fig. 28). In line 
with this result, the increase in p53 and p21 protein levels upon suppression of FIH-1 
disappeared following treatment with the chemotherapeutic drugs (Fig. 29), which implies 
that the mechanism leading to the induction in unstimulated cells is superimposed by the 
response to treatment. 
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Fig. 28: Silencing of FIH-1 does not alter apoptosis in HCT116 cells. HCT116 cells were transduced with 
shRNA against FIH-1 (shFIH-1) or empty vector (control) and treated with the indicated concentration of 
chemotherapeutic agents (A) or irradiated with 5 Gray (B) to induce an apoptotic response. Total cell lysates 
were produced after 48 h (A) or 72 h (B). Equal protein amounts were subjected to caspase-3 activity 
measurements using a fluorescent substrate. Values are shown relative to the untreated empty vector control. 
Means and SD of three samples from the linear range of the substrate cleavage reaction are plotted.  
 
 
Taken together these results imply that FIH-1-dependent hydroxylation of ASPP2 does not 
have gross effects on the apoptosis of cancer cells. As the induction of p53 may nevertheless 
be connected to ASPP2 we further characterised the connections between the two proteins. 
A double immunofluorescence staining for the endogenous proteins revealed that ASPP2 
localises predominantly to cell-cell contacts and cytoplasm while p53 is mainly located in the 
nucleus of HCT116 cells. This different localisation was also sustained under overexpression 
of ASPP2 until a very high expression level was achieved (Fig. 30). Up to this point, under 
moderate overexpression only very little ASPP2 was located in the nucleus. The absence of 
co-localisation of endogenous ASPP2 and p53 led to the question how efficiently the 
endogenous proteins can interact in HCT116 cells. 
 
 
Fig. 29: Protein levels of ASPP2, p53 and p21 
upon treatment with chemotherapeutic agents. 
HCT116 cells were transduced with shRNA 
against FIH-1 (KD) or empty vector (C) and 
treated with 1 µM doxorubicin (Doxo) or 10 µM 
etoposide (Eto). Total cell lysates of untreated 
(control) and treated samples were produced after 
48 h, equal protein amounts subjected to  
SDS-PAGE and subsequent Western blotting.  
β-actin served as a loading control. The specific 
band for FIH-1 is indicated by an asterisk. 
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Fig. 30: Discrepant intracellular localisation of ASPP2 and p53. Double immunofluorescence staining for 
ASPP2 (green) and p53 (red) in HCT116 cells left untreated (control) or transiently transfected with V5-ASPP2 
(V5-ASPP2) for 18 h. Nuclei were counterstained with DAPI. 
 
 
 
To examine this further, the endogenous proteins were recovered from whole cell lysates by 
immunoprecipitation using specific antibodies. First, an interaction of the proteins could only 
be detected when the cells had been treated with a crosslinking agent prior to lysis and 
immunoprecipitation suggesting either a minor or a transient interaction. Furthermore, even 
under addition of a crosslinker, very little ASPP2 was co-precipitated with p53 (Fig. 31) 
confirming a weak interaction of the proteins in HCT116 cells. In addition, the degree of 
interaction was independent of FIH-1 as the same amount of ASPP2 co-precipitated with p53 
in the presence or absence of the enzyme. In contrast to p53, the co-localisation of ASPP2 
was found to be obvious for other interaction partners like Bcl-2 and Par-3 (Fig. 32). 
 
 
 
Fig. 31: Interaction between ASPP2 and p53. 
HCT116 cells were transduced with shRNA 
against FIH-1 (shFIH-1) or empty vector (control). 
Before preparation of total cell lysates, cells were 
incubated with 2 mM of the crosslinking agent 
DSP for 30 min. 250 µg cell lysate were subjected 
to immunoprecipitation using 0.7 µg p53 (Ab-6) 
antibody. Immunoprecipitates were subjected to 
SDS-PAGE and subsequent Western blotting. As 
negative control immunoprecipitations were 
performed in the absence of the specific antibody 
(beads only). For p53 detection a rabbit polyclonal 
antibody was used. In parallel 25 µg of the total 
cell lysate (10% input) was subjected to  
SDS-PAGE and subsequent Western blotting.  
β-actin served as a loading control.  
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Fig. 32: Co-localisation of ASPP2 and the interaction partners Bcl-2 and Par-3. Double 
immunofluorescence staining for endogenous ASPP2 (green) and Bcl-2 or Par-3 (red) in untreated HCT116 
cells. Nuclei were counterstained with DAPI. 
 
For Bcl-2, which is also located in the cytoplasm, co-immunoprecipitation with ASPP2 was 
not detectable but Par-3 has previously been shown to be interdependently located to cell-cell 
contacts together with ASPP2 in several cancer cell lines (Cong et al., 2010; Sottocornola et 
al., 2010). In HCT116 cells a similar co-localisation was observed. Therefore we tested 
whether the localisation was also interdependent in HCT116 cells and generated stable 
ASPP2 and Par-3 knockdown cells through lentiviral transduction of shRNA, termed 
shASPP2 and shPar-3 cells, respectively. Using these cell lines, the localisation of both 
proteins was monitored by double immunofluorescence staining (Fig. 33). Again  
co-localisation of the proteins was observed in the control cells. Knockdown of each of the 
interaction partners abrogated the cell-cell contact localisation of the other protein confirming 
the interdependency. The ASPP2 antibody was found to react with high specificity in the 
immunofluorescence staining because the signal was almost completely abrogated upon 
suppression of ASPP2. In contrast, the Par-3 antibody produced a high background signal in 
the cytoplasm of the cells. However, the specific staining at cell-cell contacts disappeared 
upon depletion of ASPP2. Suppression of Par-3 had a similar effect on the localisation of 
ASPP2. In addition, the nuclear localisation of ASPP2 was increased in the absence of Par-3. 
This result suggested that the interaction with the tight junction protein may prevent a 
regulatory function of ASPP2 on p53-dependent signalling via modulation of the intracellular 
localisation in HCT116 cells. Thus, we tested whether the apoptotic response of the cells was 
altered upon disruption of the interaction between ASPP2 and Par-3. 
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Fig. 33: Interdependent localisation of ASPP2 and Par-3 in HCT116 cells. HCT116 cells were transduced 
with shRNA against ASPP2 (shASPP2), Par-3 (shPar-3) or empty vector (control) and stained for endogenous 
ASPP2 (green) and Par-3 (red) by double immunofluorescence. Nuclei were counterstained with DAPI. In 
parallel, suppression of the respective protein (KD) was monitored in comparison to control cells (C) by  
SDS-PAGE and subsequent Western blotting of equal protein amounts from total cell lysates (right panel).  
β-actin served as a loading control. 
 
To this end, we induced an apoptotic response using doxorubicin and etoposide. Indeed, an 
even more pronounced increase in nuclear localisation of ASPP2 could be observed in  
shPar-3 cells treated with the chemotherapeutic agents for 16 h (Fig. 34 A and B) as compared 
to untreated shPar-3 cells (Fig. 33). In contrast, control cells showed only little amounts of 
nuclear ASPP2 in the immunofluorescence staining upon treatment. However, the apoptotic 
response of HCT116 cells was not affected by the altered localisation of the protein 
(Fig. 34 C). In addition, apoptosis induction was found to be completely independent of the 
protein as shASPP2 cells showed no differences in caspase-3 activity upon treatment. Again, 
an increase in ASPP2 protein levels was detected following doxorubicin stimulation 
(Fig 34 D). Although this increase was partly inhibited in shASPP2 cells, no effect on 
apoptosis was observed demonstrating, that ASPP2, while induced, is not involved in the 
regulation of the response to doxorubicin. In summary, the results do not confirm a central 
role for ASPP2 in the regulation of apoptosis as reported previously. Depletion or altered 
localisation of the protein was not found to affect p53-dependent apoptosis and if at all, a 
minor interaction between ASPP2 and p53 was observed in HCT116 cells which was 
confirmed in another p53 wild-type cell line, MCF-7 (data not shown). 
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Fig. 34: Apoptosis in response to chemotherapeutic treatments is independent of ASPP2 in HCT116 cells. 
(A, B) HCT116 cells were transduced with shRNA against Par-3, treated with 1 µM doxorubicin (A) and 10 µM 
etoposide (B) for 16 h and stained for endogenous ASPP2 (green) by immunofluorescence. Nuclei were 
counterstained with DAPI. (C, D) HCT116 cells were transduced with shRNA against ASPP2 (shASPP2), Par-3 
(shPar-3) or empty vector (control) and treated with 1 µM doxorubicin (Doxo) or 10 µM etoposide (Eto). Total 
cell lysates of untreated (control) and treated samples were produced after 48 h. (C) Equal protein amounts were 
subjected to caspase-3 activity measurements using a fluorescent substrate. Values are shown relative to the 
untreated empty vector control. Means and SD of three samples from the linear range of the substrate cleavage 
reaction are plotted. (D) Equal protein amounts were subjected to SDS-PAGE and subsequent Western blotting. 
β-actin served as a loading control.  
 
 
This implies that ASPP2 predominantly binds other interaction partners instead of p53, 
particularly the tight junction protein Par-3, as ASPP2 showed a junctional localisation in all 
cancer cell lines examined including the p53 wild-type cell lines MCF-7 and U2OS (data not 
shown).  
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3.5.5 Protein interaction 
Therefore, we further studied protein interactions of ASPP2 in the presence and absence of 
the enzyme. To screen for differences in protein interactions we performed ASPP2 pull-down 
assays using metabolically labelled HCT116 cells. Following a 15 min starvation period the 
cells were incubated with 
35
S-methionine for radioactive labelling of all cellular proteins. 
Subsequently, ASPP2 was recovered from whole cell lysates by immunoprecipitation using a 
specific antibody, bound proteins were separated by SDS-PAGE using different gel 
percentages and visualised by autoradiography. This technique was expected to reveal 
differences in the interaction profile of cells transduced with shRNA against FIH-1 and 
control cells over a wide molecular weight range. Although initial experiments indicated 
differences in the interaction profile, e.g. for two proteins at approximately 45 kDa and 
200 kDa, high variations in the background signal precluded a clear statement on effects of 
FIH-1 over several experiments (data not shown).  
To circumvent the problems associated with this screening method, chosen candidates were 
directly tested for changes in protein interaction. As described before, interaction with p53 
was not altered upon FIH-1 depletion and interaction with Bcl-2 was not detectable in 
HCT116 cells. The interdependent co-localisation with Par-3 pointed towards a preference of 
ASPP2 binding to this interaction partner in HCT116 cells. Thus, we monitored the 
localisation of both proteins upon suppression of FIH-1.  
 
 
 
 
 
 
 
Fig. 35: Impact of FIH-1 on the localisation of ASPP2 and Par-3 in HCT116 cells. HCT116 cells were 
transduced with shRNA against FIH-1 (shFIH-1) or empty vector (control) and stained for endogenous ASPP2 
(green) and Par-3 (red) by double immunofluorescence. Nuclei were counterstained with DAPI. In parallel, 
suppression of FIH-1 (KD) was monitored in comparison to control cells (C) by SDS-PAGE and subsequent 
Western blotting of equal protein amounts from total cell lysates (right panel). GAPDH served as a loading 
control. 
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The double immunofluorescence staining of HCT116 shFIH-1 cells showed substantially 
impaired junctional localisation of ASPP2 and Par-3 as compared to control cells (Fig. 35). 
Both proteins were partly redistributed into the cytoplasm of shFIH-1 cells while control cells 
showed a localisation pattern which was clearly dominated by cell-cell contacts, suggesting an 
effect of FIH-1 on the localisation. We further examined whether this was also reflected by an 
altered interaction between ASPP2 and Par-3 via reciprocal co-immunoprecipitation of the 
proteins from whole cell lysates.  
Indeed, the comparison of control and shFIH-1 HCT116 cells revealed impaired interaction 
upon depletion of the enzyme while total protein levels of ASPP2 and Par-3 were not affected 
(Fig. 36). The interaction was not completely disrupted by silencing of FIH-1 but observed to 
be significantly reduced by 30% in comparison to control cells in several experiments 
regardless of which interaction partner was precipitated.  
 
A        
 
 
 
 
 
B 
 
 
 
 
 
Fig. 36: Impact of FIH-1 on the interaction of ASPP2 and Par-3. HCT116 cells were transduced with shRNA 
against FIH-1 (shFIH-1) or empty vector (control). (A) 500 µg cell lysate were subjected to immunoprecipitation 
using 5 µg ASPP2 antibody. (B) 500 µg cell lysate were subjected to immunoprecipitation using 5 µg Par-3 
antibody. As negative control immunoprecipitations were performed in the absence of the specific antibody 
(beads only). Immunoprecipitates were subjected to SDS-PAGE and subsequent Western blotting. In parallel 
25 µg of the total cell lysate (5% input) were subjected to SDS-PAGE and subsequent Western blotting. β-actin 
served as a loading control for input samples. Significance of the reduction in protein interaction was tested over 
5 (A) and 4 (B) independent experiments where band intensities were quantified relative to control cells. 
Statistical significance was tested by Student’s t-test where * indicates p < 0.05 and ** indicates p < 0.01. 
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To assess whether the impact of FIH-1 on the interaction between ASPP2 and Par-3 is a 
general phenomenon, other cancer cell types were examined following suppression of FIH-1. 
H441 lung carcinoma cells which possess a more epithelial phenotype with more junctional 
contacts throughout the monolayer in comparison to HCT116 cells also showed an altered 
localisation of ASPP2 and Par-3 in the double immunofluorescence staining upon 
transduction with shRNA against FIH-1. In this case the proteins were not completely 
redistributed into the cytoplasm but the localisation of residual ASPP2 remaining at the  
cell-cell contacts was found to be highly disorganised in comparison to control cells 
(Fig. 37 A). In addition, two different colon cancer cell lines, CaCo-2 and DLD-1, were 
examined. Because these cell lines formed very thick monolayers, it was difficult to monitor 
all cell contacts present on one image section by confocal microscopy as the junctions were 
distributed over different levels of the samples. However, changes in the intracellular 
localisation of ASPP2 and Par-3 were not observed in shFIH-1 cells in comparison to the 
controls in these two cell lines (Fig. 37 B and C).  
We further examined the interdependent localisation of ASPP2 and Par-3 in these cell lines. 
In H441 cells the junctional localisation was disrupted upon depletion of each of the 
interaction partners by lentiviral transduction of the respective shRNA (Fig. 38 A). In 
contrast, CaCo-2 cells did not show changes in ASPP2 localisation upon suppression of Par-3 
(Fig. 38 B). These results imply that suppression of FIH-1 only affects the localisation of 
ASPP2 and Par-3 in cells where the localisation of the proteins depends on the presence of the 
interaction partner. Interestingly, the interdependent localisation of the proteins was not 
correlated to the p53 status of the cells as HCT116 cells harbour wild-type p53 while the 
tumor suppressor is mutated in H441 cells.  
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Fig. 37: Impact of FIH-1 on the localisation of ASPP2 and Par-3 in various cancer cell lines. H441 (A), 
CaCo-2 (B) and DLD-1 (C) cells were transduced with shRNA against FIH-1 (shFIH-1) or empty vector 
(control) and stained for endogenous ASPP2 (green) and Par-3 (red) by double immunofluorescence. Nuclei 
were counterstained with DAPI. In parallel, suppression of FIH-1 (KD) was monitored in comparison to control 
cells (C) by SDS-PAGE and subsequent Western blotting of equal protein amounts from total cell lysates. 
GAPDH served as a loading control. 
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Fig. 38: Interdependent localisation of ASPP2 and Par-3 is cell type dependent. H441 (A) and CaCo-2 (B) 
cells were transduced with shRNA against ASPP2 (shASPP2), Par-3 (shPar-3) or empty vector (control) and 
stained for endogenous ASPP2 (green) and Par-3 (red) by double immunofluorescence. Nuclei were 
counterstained with DAPI. In parallel, suppression of the respective protein (KD) was monitored in comparison 
to control cells (C) by SDS-PAGE and subsequent Western blotting of equal protein amounts from total cell 
lysates. GAPDH served as a loading control. 
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To show that the effect of FIH-1 on the localisation of ASPP2 and Par-3 was dependent on 
hydroxylation of ASPP2 by FIH-1, cell lines showing the altered localisation upon FIH-1 
suppression were treated with the hydroxylase inhibitor DMOG. Indeed, inhibition of FIH-1 
activity had a similar effect on ASPP2 localisation like depletion of the enzyme in HCT116 
and H441 cells as monitored by immunofluorescence staining (Fig. 39). The junctional 
localisation was even decreased further upon DMOG treatment of shFIH-1 cells 
demonstrating that inhibition of residual FIH-1 potentiated the effect. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 39: Impact of FIH-1 on the localisation of ASPP2 depends on the activity of the enzyme. HCT116 (left 
panel) and H441 (right panel) cells were transduced with shRNA against FIH-1 (shFIH-1) or scrambled shRNA 
(control) and treated with 1 mM (HCT116) and 500 µM (H441) DMOG for 16 h. Subsequently, cells were 
stained for endogenous ASPP2 (green) by immunofluorescence. Nuclei were counterstained with DAPI.  
 
3.5.6 Adhesion and migration 
In the last part of the study, we assessed the physiologic consequences of the altered 
interaction and localisation of ASPP2 triggered by FIH-1-dependent hydroxylation. As an 
impaired integrity of tight junctions is expected to lead to the separation of the cells in the 
monolayer, adhesive as well as migratory capacities of the cells were investigated. 
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Fig. 40: Adhesion of cancer cells is slightly increased upon suppression of FIH-1 or ASPP2. HCT116 (left 
panel) and H441 (right panel) cells were transduced with shRNA against FIH-1 (shFIH-1), ASPP2 (shASPP2) or 
scrambled shRNA (control) and tested for adhesion capacity. Following 2 h on collagen-coated culture vessels, 
adherent cells were quantified by fluorescent labelling using calcein-AM. Values are shown relative to control 
cells. Combined values of two independent experiments with ten independent samples are plotted. 
 
We analysed adhesion and migration in HCT116 and H441 cells depleted for FIH-1 by 
lentiviral transduction. As control for the implication of ASPP2 in these processes, shASPP2 
cells were examined as well. Adhesion of the cells was significantly increased approximately 
10% upon suppression of FIH-1 and ASPP2 in both cell lines (Fig. 40) suggesting a change 
potentially mediated by FIH-1-dependent hydroxylation of ASPP2.  
 
 
 
 
 
 
 
 
 
 
Fig. 41: Migration is reduced upon silencing of FIH-1 while ASPP2 depletion increases cancer cell 
motility. HCT116 (left panel) and H441 (right panel) cells were transduced with shRNA against FIH-1  
(shFIH-1), ASPP2 (shASPP2) or scrambled shRNA (control), grown to confluence on collagen-coated culture 
dishes and subjected to scratch assays. Wound closure was quantified as reduced distance between the scratch 
ends after 8 h in comparison to the initial scratch at eleven different points of each scratch.  
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Migration of the cells was slightly decreased following silencing of FIH-1 but this effect was 
independent of ASPP2 as depletion of the protein triggered the migratory potential of the cells 
(Fig. 41). Moreover, the effects on migration were not significant due to high variation of the 
scratch ends. Taken together, adhesion and migration assays did not reveal a substantial effect 
of hydroxylation of ASPP2.  
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Although hydroxylation was previously thought to be rather uncommon, it is more and more 
recognized as an important posttranslational modification mediating substantial effects on the 
interaction profile of proteins. One well-documented example is collagen where prolyl and 
lysyl hydroxylation mediate the stability of the peptide triple helices (Uitto and Lichtenstein, 
1976). Another well-characterised example is the hydroxylation of α-subunits of the 
transcription factor HIF. In this case, prolyl hydroxylation triggers interaction with the 
recognition subunit of the E3 ubiquitin ligase responsible for ubiquitination and proteasomal 
degradation of HIF, the von Hippel-Lindau protein (Kaelin and Ratcliffe, 2008). In contrast, 
HIF asparaginyl hydroxylation blocks binding to the transcriptional co-activator p300/CBP 
(Lisy and Peet, 2008) thereby inhibiting HIF transcriptional activity. The hydroxylation of 
HIF-1α was the first reaction found to be catalysed by FIH-1. Over the last decade, it could be 
shown that some ARD-containing proteins are also hydroxylated by FIH-1. However, to date, 
no obvious physiologic effect or impact on protein interaction profiles of substrates could be 
revealed for ARD-hydroxylation (Cockman et al., 2009b; Coleman and Ratcliffe, 2009). In 
our study we demonstrate that ARD-hydroxylation of ASPP2 by FIH-1 significantly alters the 
interaction profile as well as the subcellular localisation of ASPP2. In addition we report a 
new function of FIH-1-dependent hydroxylation in the modulation of protein interaction 
suggesting effects not only on ASPP2 but potentially also on other ARD-containing FIH-1 
substrates. Alignments with currently known FIH-1 substrates demonstrated high sequence 
similarities to ASPPs. In vitro experiments directly identified ASPP2 as a new substrate for 
FIH-1. We detected a single hydroxylation site for FIH-1 in the ARD of ASPP2, N986, which 
was targeted by FIH-1 in vitro as well as in cells. In contrast to ASPP2, the conserved protein 
family member iASPP was not hydroxylated by FIH-1 at the corresponding potential target 
asparagine which proves the specificity of ARD-hydroxylation despite frequent occurrence.  
 
4.1 ASPP2 is hydroxylated by FIH-1 at N986 
The FIH-1 hydroxylation site N986, identified in this study, is situated within the ARD of 
ASPP2 in the loop region between two ankyrin repeats (Fig. 42). This position of the target 
amino acid is conserved among all ARD-containing substrates of the enzyme although the 
sequence of the hydroxylation site and even the hydroxylated residue can vary.  
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Fig. 42: Position of the FIH-1 
hydroxylation site in the ARD of 
ASPP2. Schematic representations of the 
solution structure of the ARD and 
adjacent regions of ASPP2 (PDI entry 
4A63_B) (Canning et al., 2012). α-helices 
are shown as cylinders and β-sheet 
structures are indicated by arrows. The 
hydroxylation site N986 in the loop 
region between two ankyrin repeats is 
highlighted by a red circle. The structure 
was plotted using the Cn3D 4.3 
macromolecular structure viewer (NCBI). 
 
Our data on the hydroxylation of ASPP2 demonstrate that a second asparagine two amino 
acids upstream of N986 was neither targeted by FIH-1 in vitro nor in cultured cells. Thus, 
despite the high sequence variability of the hydroxylation site, the target amino acid has to be 
present in a certain structural context for FIH-1-dependent hydroxylation. As a high 
background signal was observed in hydroxylase activity assays on the whole ARD of ASPP2 
upon mutation of N986 in vitro, we examined the presence of other FIH-1 hydroxylation sites 
in ASPP2. The background activity was not due to hydroxylation of N984 as shown by 
mutation studies using single and double mutants for N984 and N986. Furthermore, FIH-1 
activity was almost completely abrogated using short ASPP2 peptides with a single mutation 
of N986. In addition, hydroxylation of N984 could not be detected in MS analyses on ASPP2 
purified from cultured cells. As no additional potential FIH-1 hydroxylation site could be 
detected, the background activity on the long substrate proteins in the in vitro assays was most 
likely due to uncoupled activity of the enzyme which is also supported by variations in 
background activity observed for different substrate preparations. Taken together, we propose 
that N986 is a single hydroxylation site for FIH-1 present in ASPP2. Using short peptides in 
vitro we could demonstrate specificity of the hydroxylation reaction using the hydroxylase 
inhibitor NOG. Furthermore, the Km value of 75 µM that we determined for hydroxylation of 
ASPP2 N986 in the context of a short peptide was comparable to those of substrates 
previously identified (Wilkins et al., 2009). Importantly, efficient hydroxylation of ASPP2 
N986 was also detected in cultured cells by MS analysis. Due to the high molecular weight 
and the amino acid sequence of ASPP2, digestion of the endogenous protein did not yield 
sufficient amounts of peptide for the analysis. Therefore, we purified overexpressed ASPP2 
from HEK293T cells for the MS experiments. Remarkably, endogenous FIH-1 expressed in 
the cells was capable of hydroxylating the majority of overexpressed ASPP2 which indicates 
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a high affinity for the substrate. Co-transfection of the enzyme further triggered hydroxylation 
of N986. In addition, similar to the in vitro studies, application of the hydroxylase inhibitor 
DMOG almost completely blocked hydroxylation. Finally, suppression of FIH-1 expression 
through lentiviral transduction of shRNA clearly reduced but not completely abrogated 
hydroxylation of ASPP2 verifying the enzyme-substrate relation. The residual hydroxylation 
observed is likely to be catalysed by the remaining 10% of the enzyme amount in shFIH-1 
cells because previous studies using a more efficient knockdown produced by siRNA 
transfection could completely block hydroxylation of other ARD-containing FIH-1 substrates 
(Webb et al., 2009; Yang et al., 2011a). All together these results clearly demonstrate that  
FIH-1 is the hydroxylase responsible for the modification and it is unlikely that another 
hydroxylase can compensate for depletion of FIH-1 in the case of ASPP2. The residual 
hydroxylation upon silencing of FIH-1 by shRNA transduction again points to a very high 
affinity of FIH-1 for ASPP2. Supporting this hypothesis, a strong interaction between enzyme 
and substrate could be observed in interaction studies in vitro with a higher binding affinity of 
FIH-1 for ASPP2 as compared to the well-characterised substrate HIF-1α. 
 
4.2 Substrate recognition by FIH-1 
4.2.1 Differences between HIF-1α and ASPP2 
The stronger interaction observed between GST-ASPP2 protein fragments and FIH-1 as 
compared to GST-HIF-1α is in line with previous results on ARD-containing FIH-1 substrates 
suggesting a distinct substrate recognition mechanism which is different for ARD-containing 
substrates as compared to HIF-1α. For mouse Notch1 an increase in substrate length was 
found to improve binding to FIH-1 substantially while the interaction with HIF-1α substrates 
was not affected. In general, Notch substrate handling was shown to be very similar to ASPP2 
because Notch substrates bound FIH-1 more efficiently than HIF-1α (Wilkins et al., 2009) 
and we also observed a stronger binding affinity of FIH-1 to ASPP2 protein fragments as 
compared to HIF-1α. While the conformation of the ARD in solution was observed to be 
highly structured (Kohl et al., 2003; Coleman et al., 2007), the CTAD of HIF-1α has been 
reported to pre-exist in an unstructured form in solution and to adopt a structured 
conformation after binding to FIH-1 (Dames et al., 2002). Despite these differences, both 
substrates were found to adopt a largely extended conformation in complex with FIH-1 with 
similar interaction interfaces (Elkins et al., 2003; Coleman et al., 2007).  
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Consequently, to enable accessibility of the target amino acid and to achieve the required 
extended conformation, ARD-containing FIH-1 substrates have to undergo a conformational 
change in terms of binding to the enzyme. These differences in the secondary structure may 
result in different hydroxylation efficiencies detected for ASPP2 and HIF-1α protein 
fragments. The HIF-1α wild-type CTAD was hydroxylated ten times more efficiently as 
compared to ASPP2 potentially because unfolding of the ARD is required for hydroxylation. 
In addition, hydroxylation of ASPP2 was augmented when short 20 amino acid peptides were 
tested for FIH-1 activity instead of longer 240 amino acids protein regions. These results 
support the hypothesis that the efficiency of the hydroxylation reaction is in part determined 
by the secondary and tertiary structure of the substrate. However, the in vitro data on 
hydroxylation efficiency may not apply to the in vivo situation as we still detected a large part 
of overexpressed ASPP2 hydroxylated in cells with substantially reduced FIH-1 protein 
levels. Together with the fact that the major proportion of overexpressed ASPP2 can be 
hydroxylated by endogenous FIH-1 this implies a higher hydroxylation rate for this substrate 
in cells. Of note, different hydroxylation levels have been reported for other ARD-containing 
substrates using quantitative MS analyses. For human Notch1 the endogenous protein was 
found to be almost 90% hydroxylated at N1956 in HEK293T cells (Coleman et al., 2007) 
while overexpressed Rabankyrin-5 was found to be hydroxylated 20% to 55% depending on 
the hydroxylation site, under co-expression of the HIF-1α CTAD which may compete for 
hydroxylation (Singleton et al., 2011). The latter report also compared the oxygen-
dependency of HIF-1α CTAD and Rabankyrin-5 hydroxylation and revealed that ARD 
hydroxylation seems to be more sensitive to depletion of oxygen as compared to the 
transcription factor indicating a more efficient hydroxylation of HIF-1α. However, further 
quantitative studies on the hydroxylation levels of endogenous ARD-containing FIH-1 
substrates in comparison to HIF-1α are required to determine the activity of FIH-1 in vivo. 
Particularly such analyses may help to answer the question whether HIF signalling is affected 
by ARD-hydroxylation as a recent study on overexpression of Gankyrin in mice suggested 
(Liu et al., 2013). Although we could not perform such an analysis on endogenous ASPP2, 
our results imply that the enzyme activity on the protein is similar to Notch1 as even the 
overexpressed protein was hydroxylated to a great extent. 
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4.2.2 ASPP2 but not iASPP is hydroxylated by FIH-1 
In contrast to ASPP2, we observed that the conserved protein family member iASPP was not 
modified by FIH-1 at the corresponding asparagine residue. Regarding the promiscuous 
character of the enzyme and the high conservation of the ARD, it was surprising that iASPP 
did not undergo hydroxylation in our in vitro study, although short peptides which were 
observed to produce the most reliable results were tested. In addition, the peptides are not 
expected to adopt a secondary structure precluding hydroxylation. Furthermore, although 
there are some differences in the primary sequence (Fig. 43 A), the C-termini of ASPP2 and 
iASPP, particularly the ARD, are highly conserved in the solution structure of the proteins 
(Fig. 43 B).  
Our results indicate that the amino acid sequence, especially the residues in close proximity to 
the target asparagine, may also determine hydroxylation efficiency thereby precluding 
hydroxylation of iASPP while ASPP2 can be modified. A very recent report, which 
demonstrates that the primary sequence contributes to distinct characteristics of ARD 
substrates in contrast to HIF-1α, supports this hypothesis (Wilkins et al., 2012). This study 
revealed that the kinetics of the hydroxylation reaction for ARD-containing substrates are 
affected by amino acids in close proximity of the hydroxylated residue. In addition, the 
authors suggest that single amino acid substitutions in this region disrupt the substrate 
conformation which is required for FIH-1-dependent hydroxylation. This might also apply to 
ASPP2 and iASPP which differ in the primary amino acid sequence at the -3, +1 and +2 
position relative to the hydroxylation site. These differences potentially enable hydroxylation 
of ASPP2 while iASPP was not able to serve as substrate for FIH-1 in vitro. The +1 position 
is potentially crucial in this context because the majority of the FIH-1 substrates show 
hydrophobic residues at this position (alanine, valine or isoleucine). In contrast, iASPP shows 
a polar serine residue one amino acid downstream of the target asparagine which may 
interfere with hydroxylation as only one other hydroxylation site in Rabankyrin-5 also shows 
a serine at the same position. In summary, despite the low substrate specificity of FIH-1 
distinct characteristics may be required in the case of ARD-containing proteins as well.  
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Fig. 43: Primary and secondary structure conservation of the ARD regions of ASPP2 and iASPP. 
Alignments of protein sequences of ASPP2 (aa 915-1056) and iASPP (aa 616-757) containing the whole ARD 
and adjacent regions. (A) Amino acid alignment. Identical residues are coloured in red and non-conserved amino 
acids are shown in green. Alignment was created using the CLC Bio sequence viewer 6. N986 and N687 are 
indicated by asterisk. (B) Alignment of the schematic representations of the solution structure of the ARD and 
adjacent regions of ASPP2 (PDI entry 4A63_B) (Canning et al., 2012) and iASPP (PDI entry 2VGE_A) 
(Robinson et al., 2008). Identical residues are shown in red and non-conserved amino acids are coloured in blue. 
α-helices are shown as cylinders in pink for ASPP2 and blue for iASPP. The hydroxylation site N986 in the loop 
region between two ankyrin repeats is shown in yellow. Non-aligned residues at the N-terminal region are shown 
in grey. Alignment was created using VAST similar structures (Gibrat et al., 1996). Scheme was generated using 
the Cn3D 4.3 macromolecular structure viewer (NCBI).  
 
4.2.3 Implications for the identification of new substrates 
The fact that only one out of two highly conserved proteins is hydroxylated by FIH-1 may be 
beneficial for the prediction of additional new substrates and for the definition of a consensus 
FIH-1 hydroxylation motif. The low specificity of the enzyme makes it difficult to predict 
from the primary sequence of the protein whether an ARD can serve as FIH-1 hydroxylation 
site. A very recent study detected hydroxylation of serine and leucine residues catalysed by 
FIH-1 in the context of a consensus ankyrin repeat substrate peptide further emphasising the 
promiscuity of the enzyme (Yang et al., 2013). 
* 
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Fig. 44: Primary amino acid 
sequence conservation between 
ASPP1 and ASPP2. Alignment 
of protein sequences of ASPP2 
(aa 915-1056) and ASPP1 
(aa 877-1018) containing the 
whole ARD and adjacent 
regions. Identical residues are 
coloured in red and  
non-conserved amino acids are 
shown in green. Alignment was 
created using the CLC Bio 
sequence viewer 6. N986 and 
N948 are indicated by asterisk. 
 
Nevertheless, our study highlights the importance of the amino acid sequence in the close 
proximity of the target asparagine. Especially the +1 position may be crucial for the 
identification of new substrates as this is the only position out of the amino acids conserved 
among 50% of all substrates differing between ASPP2 and iASPP. The 50% consensus 
sequence “AAXXXXXXXXXXLLXXGADVNAXDXXGXXPLHXAXXXXXX” did not 
change upon inclusion of ASPP2 but the importance of the downstream amino acid is 
emphasised by the comparative studies on iASPP and ASPP2. As the substrate requirements 
for FIH-1 are difficult to define, the identification of specific residues which may be crucial 
for hydroxylation is likely to facilitate identification of new FIH-1 substrates.  
With respect to the third family member, ASPP1, hydroxylation by FIH-1 is very likely to 
occur as the C-termini of ASPP1 and ASPP2 are highly conserved. The primary amino acid 
sequence of the ARD and adjacent regions only slightly differs in ASPP1 (Fig. 44). 
Nonetheless, further studies on the putative FIH-1 target amino acid in ASPP1, N948, are 
required to demonstrate hydroxylation of the protein in cells. We anticipate that the 
physiologic effects of such a modification of ASPP1 are difficult to determine as the protein is 
mostly involved in the control of proliferation and apoptosis. In our studies we did not detect 
any effects of FIH-1 suppression on these processes suggesting that FIH-1-dependent 
hydroxylation of ASPP1 does not have an impact in this regard. However, similar to the 
situation we observed for ASPP2, other cellular functions, e.g. lymphatic vessel assembly 
where ASPP1 has been shown to be relevant (Hirashima et al., 2008), may be affected by 
modulation of protein interaction.  
* 
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4.3 Impact of FIH-1-dependent hydroxylation of ASPP2 
4.3.1 ASPP2 protein stability is not regulated by FIH-1 
Although the secondary structure of consensus ankyrin repeat proteins is stabilised by  
FIH-1-dependent hydroxylation (Hardy et al., 2009; Kelly et al., 2009) neither the half-life 
nor thermodynamic stability of a full length ARD-containing FIH-1 substrate were shown to 
be affected by hydroxylation to date (Devries et al., 2010; Singleton et al., 2011). Very 
recently, the thermal stability of a fragment of AnkyrinR (ankyrin repeats 13-24) was shown 
to be moderately increased upon hydroxylation by FIH-1 (Yang et al., 2011b) indicating an 
impact of hydroxylation on secondary structure stability. However, this was not correlated to 
a difference in protein stability. In contrast, the interaction of this fragment with CDB3, a 
known interaction partner of this region of AnkyrinR was impaired.  
Regarding ASPP2, we attempted to directly determine the half-life of the protein but two 
different methods did not lead to consistent results in this case. First, our results do not 
confirm the regulation of ASPP2 by the 26S proteasome which has been reported previously 
(Zhu et al., 2005) because the proteasome inhibitor MG132 did not increase ASPP2 protein 
levels although functionality of the drug was proven by p53 induction. In addition, even 24 h 
of cycloheximide treatment were not sufficient to detect any degradation of the endogenous 
protein. Furthermore, we also examined exogenously expressed ASPP2 using the same 
approach and pulse chase experiments to obtain clearer results, but overexpression of the 
protein led to the induction of apoptosis and we were not able to differentiate between 
reduction due to apoptosis and degradation in these experimental settings. Taken together, for 
endogenous ASPP2, we demonstrated high protein stability. Therefore alterations of protein 
stability would be expected to affect the overall levels of the protein which was not the case 
upon silencing of FIH-1. As we did not detect any differences in total protein amounts of 
ASPP2 upon silencing of FIH-1 we propose that FIH-1-dependent hydroxylation does not 
substantially regulate stability or production of endogenous ASPP2.  
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4.3.2 Cell proliferation and apoptosis are not affected by FIH-1 
Further comparisons between cells depleted of FIH-1 and control cells did not reveal 
differences in the proliferation of HCT116 cells, although p53 and p21 were induced on the 
protein level which has previously been reported to decrease proliferation in several wild-type 
p53 cell lines (Pelletier et al., 2011). Moreover, we were not able to detect differences in the 
interaction of ASPP2 and p53 in the presence or absence of FIH-1. In line with this, we did 
not observe any changes in the mortality of the cells upon silencing of FIH-1 under control or 
stress conditions, as already reported by Pelletier et al. for wild-type p53 cancer cells. This is 
in contrast to another report which demonstrated that FIH-1 can trigger survival of renal 
cancer cells through suppression of apoptosis (Khan et al., 2011). It has also been shown that 
osteosarcoma cells overexpressing FIH-1 display enhanced tumor growth in a xenograft 
mouse model while silencing of FIH-1 in these cells did not affect proliferation (Kuzmanov et 
al., 2012). In summary, several studies on FIH-1 suggest that the physiologic effect of FIH-1 
on survival decisions depends on the cell type examined.  
In HCT116 cells bearing wild-type p53, we found that ASPP2 does not co-localise with p53 
which may prevent an involvement in apoptotic signalling. Endogenous ASPP2 was mainly 
localised to cell-cell contacts due to the interaction with Par-3 while p53 was predominantly 
located in the nucleus. Even overexpression of ASPP2 did not lead to nuclear localisation of 
the protein until a certain level of expression was exceeded. In line with previous publications 
overexpression of ASPP2 led to the induction of apoptosis in HCT116 cells which is 
potentially due to an altered cytoplasmic localisation of the protein enabling regulation of p53 
(Samuels-Lev et al., 2001; Kobayashi et al., 2005). In fact, few studies were able to confirm 
the role of ASPP2 in apoptosis regulation for the endogenous protein. A very recent report 
demonstrates that ASPP1 and ASPP2 trigger the apoptotic response of retinal ganglion cells 
to optic nerve damage in vivo in a p53-dependent manner (Wilson et al., 2013). In line with 
this, studies on drosophila ASPP (dASPP), the homolog of mammalian ASPP1 and ASPP2, 
report an important role for dASPP in retinal development but this was not due to altered 
apoptosis but rather to modulation of cell-cell adhesion (Langton et al., 2009). Similarly, in 
mice ASPP2 was shown to control polarity and proliferation of retinal precursor cells during 
CNS development (Sottocornola et al., 2010) but it is not clear whether this function is related 
to p53 signalling. Two different studies on mice heterozygous for ASPP2 provide evidence 
that the observed tumor suppressive activity of the protein only partly depends on the 
presence of p53 suggesting a tumor type dependent regulation of p53 by ASPP2 (Vives et al., 
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2006; Kampa et al., 2009). In HCT116 cells we found very small amounts of ASPP2 
interacting with p53 which indicates that the protein may prefer other interaction partners 
such as Par-3 which maybe prevents a regulation of p53 function. In order to examine 
whether the localisation of ASPP2 indeed precludes regulation of p53-dependent apoptosis, 
we disrupted the junctional localisation of the protein by depletion of the interaction partner 
Par-3. Indeed, this led to a redistribution of ASPP2 with small amounts of the endogenous 
protein also localising to the nucleus. However, we were still not able to detect differences in 
the apoptotic response of HCT116 cells. Neither depletion of ASPP2 nor the redistribution of 
the protein through silencing of Par-3 affected apoptosis induced by chemotherapeutic agents 
although one of the agents used, doxorubicin, induced ASPP2 on the protein level which 
initially suggested a role for ASPP2 in this apoptotic response. A very recent report provides a 
possible explanation for these results as it connects ASPP2 to Ras signalling (Wang et al., 
2013a). ASPP2 was shown to enhance Ras signalling thereby triggering p53-dependent 
apoptosis. This signalling axis might be disrupted by an activating KRas mutation in HCT116 
cells potentially uncoupling Ras signalling from ASPP2.  
Because, the stimulation of p53-dependent apoptosis by ASPP2 obviously depends on the cell 
type examined and the status of other cellular signalling factors particularly in cancer cells we 
investigated MCF-7 breast carcinoma cells bearing wild-type p53 in the absence of Ras 
mutations. However, we were not able to detect any interaction of endogenous p53 and 
ASPP2 confirming the results for HCT116 cells where a weak interaction of the proteins 
could be detected only following addition of a crosslinking agent. Nevertheless, the situation 
in untransformed primary cells may be completely different and ASPP2 may be able to 
stimulate p53-dependent apoptosis in these cells. The upregulation of ASPP2 following 
stimulation of an apoptotic response with doxorubicin supports this hypothesis. A similar 
upregulation of ASPP1 in response to treatment with the chemotherapeutic agent resveratrol 
has previously been reported to sensitise breast carcinoma cells to apoptosis induction (Shi et 
al., 2011). In this case, the increase of ASPP1 was found to be mediated by E2F-1 on the 
transcriptional level. As ASPP2 was also shown to be a transcriptional target of E2F (Chen et 
al., 2005) and doxorubicin treatment was found to lead to the induction of E2F transcription 
factors (Martinez et al., 2010) a similar mechanism potentially leads to the increased ASPP2 
protein levels in HCT116 cells following doxorubicin stimulation. Regarding the cell type 
specific effects of ASPP2 on apoptosis this regulatory mechanism may be important in other 
cell types, although an impact on apoptosis induction in HCT116 cells could not be observed.  
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In summary, the stimulatory function of ASPP2 on p53-dependent apoptosis does not seem to 
be a general phenomenon and further studies are required to fully elucidate the mechanism by 
which ASPP2 mediates the increase in p53 transactivating function on promoters of 
proapoptotic genes in some cell types. This may also contribute to an explanation why ASPP2 
does not necessarily have the same impact on apoptotic signalling. 
 
 
4.3.3 Protein interactions of ASPP2 are regulated by FIH-1  
Even if neither the thermodynamic stability nor the half-life of an ARD-containing substrate 
is altered upon hydroxylation by FIH-1, the conformation of the protein can change due to 
hydroxylation and this may modulate the affinity to protein interaction partners. We 
confirmed this hypothesis, showing for the first time that protein interaction and localisation 
of an ARD-containing FIH-1 substrate are altered upon silencing of FIH-1 in two different 
cell lines. HCT116 shFIH-1 cells displayed reduced interaction of ASPP2 with Par-3 which 
led to an intracellular redistribution of ASPP2 from cell-cell contacts to the cytoplasm. The 
more epithelial-like H441 pulmonary adenocarcinoma cells demonstrated an obviously 
disorganized localization of ASPP2 at cell-cell contacts. In addition, these effects were found 
to depend on the hydroxylase activity of FIH-1 as the effect could be mimicked by the use of 
the hydroxylase inhibitor DMOG. In contrast, the interaction of ASPP2 with the tumor 
suppressor p53 was not affected by FIH-1-dependent hydroxylation. Taken together, these 
results suggest a distinct role for FIH-1 in formation and maintenance of cell-cell junctions 
through regulation of the ASPP2-Par-3 interaction which was previously shown to be relevant 
for these processes (Cong et al., 2010; Sottocornola et al., 2010).  
The impact of FIH-1 on this interaction varied between different cancer cell lines, since 
CaCo-2 and DLD-1 colon cancer cells did not show an altered localisation of the proteins 
upon silencing of FIH-1. Further experiments on the function of ASPP2 and Par-3 in H441 
and CaCo-2 cells revealed that the effect of FIH-1 required the interdependent localisation of 
both proteins. In HCT116 as well as in H441 cells we observed that the junctional localisation 
was disrupted upon silencing of one of the interaction partners while CaCo-2 cells showed a 
cell-cell contact localisation of ASPP2 irrespective of Par-3. This suggests another 
mechanism directing ASPP2 towards tight or adherens junctions which functions 
independently of Par-3. 
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Because tight and adherens junctions often display a cell-type specific composition with large 
complexes containing multiple proteins involved (Schneeberger and Lynch, 2004), it is 
possible that the lack of the scaffolding protein Par-3 can be compensated for in some cell 
types. Thus, the hydroxylation of ASPP2 by FIH-1 may only exert its effects in certain cell 
types through modulation of ASPP2-Par-3 interaction. Moreover, additional factors which 
stabilise the interaction may be present in some cell types and override more subtle effects of 
FIH-1-dependent hydroxylation on protein interaction. In addition, it is also possible that a 
trimeric complex of Par-3, ASPP2 and an unknown junctional protein is required for the  
cell-cell contact localisation of ASPP2 and Par-3, as the hydroxylation site is located in the  
C-terminus of ASPP2 while Par-3 interaction is mediated by the N-terminal part of ASPP2. A 
protein interacting with the C-terminal part of ASPP2 and Par-3 at the same time may be 
required to stabilise the protein interaction in some cell types. Importantly, the interaction 
between ASPP2 and Par-3 was not completely abrogated upon suppression of FIH-1, but only 
reduced, with, however, profound effects on the intracellular localisation of ASPP2 in 
HCT116 and H441 cells. The consequences on protein interaction may also depend on the 
quality of the FIH-1 knockdown on the protein level, as the MS analysis revealed that 
suppression of 90% of the enzyme in HEK293T cells was not sufficient to completely abolish 
hydroxylation of overexpressed ASPP2. The amount of FIH-1 necessary for hydroxylation of 
endogenous ASPP2 may vary, depending on the activity of the enzyme and the levels of other 
substrates present in the cell. Consequently, variations in FIH-1 activity potentially lead to 
different results depending on the cell line examined. Indeed, the effect for H441 cells was 
most prominent when a very high knockdown efficiency of more than 95% was achieved for 
FIH-1.  
Taken together, the FIH-1 mediated effect on ASPP2-Par-3 interaction is probably a 
consequence of ASPP2 hydroxylation which directly triggers the interaction with Par-3 or 
indirectly improves binding through modulation of interaction with additional factors. 
However, our data propose a model, where FIH-1-dependent hydroxylation of ASPP2 triggers 
the interaction with Par-3 while neither binding of p53 nor p53-dependent signalling are 
affected (Fig. 45). Consequently, hydroxylation promotes the junctional localisation of 
ASPP2 and Par-3. 
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Fig. 45: Model for the regulation  
of ASPP2 by FIH-1-dependent 
hydroxylation. ASPP2 is modified by  
FIH-1 on the posttranslational level 
through hydroxylation of N986. In 
contrast, the conserved family member 
iASPP is not hydroxylated by FIH-1. 
The hydroxylation of ASPP2 does not 
modulate p53-dependent apoptosis but 
triggers the interaction between 
ASPP2 and Par-3 and the junctional 
localisation of this protein complex.  
 
 
 
 
4.3.4 Physiological effects of altered protein interactions of ASPP2 – future 
perspectives 
As ASPP2 and Par-3 are involved in the formation of tight junctions in epithelial cells, 
alterations in interaction and localisation of the proteins may affect the integrity and barrier 
function of epithelia. To examine theses processes experimentally, we tried to directly 
quantify junctional integrity in cooperation with H. Mairbäurl, University of Heidelberg, 
through measurement of monolayer permeability and transepithelial electrical resistance 
(TER) upon depletion of FIH-1 in cultured tumor cells. Despite considerable effort, we were 
not able to generate cells which exhibited stable suppression of FIH-1 following lentiviral 
transduction and show an interpretable TER simultaneously. In addition, the FIH-1-dependent 
effect on ASPP2 localisation was not present in all cell lines examined, e.g. CaCo-2 cells, 
which are often used as model system to study epithelial integrity and exhibit a high TER, did 
not show an altered localisation of ASPP2 upon silencing of FIH-1. Thus, we were not able to 
elucidate whether a reduced interaction between ASPP2 and Par-3 indeed affects tight 
junction integrity per se. Alternatively, an effect may only occur under distinct circumstances, 
e.g. pathophysiological conditions such as severe hypoxia. Interestingly, FIH-1-deficient mice 
do not display developmental defects but rather metabolic disorders (Zhang et al., 2010). This 
rather suggests effects under pathophysiological conditions. In contrast, the mouse model for 
ASPP2 deficiency displays substantial defects in CNS development as a consequence of 
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deregulated polarity and expansion of neuronal progenitor cells (Sottocornola et al., 2010) 
which may be due to defects in tight junction integrity.  
To date, the interaction between ASPP2 and Par-3 and the physiologic effects have 
exclusively been characterized in epithelial cells. In these cells, the interaction was found to 
regulate particularly the early formation and the maintenance of cell-cell contacts (Cong et al., 
2010). Our data suggest an alternative mechanism which can direct ASPP2 to cell-cell 
contacts in the absence of Par-3 in CaCo-2 cells. Thus, ASPP2 probably interacts with other 
junctional proteins and further studies are required to elucidate the cell type dependent 
mechanisms which trigger the junctional localisation of ASPP2. It is now interesting to 
further explore the role of ASPP2 for tight junction formation or integrity in different cell 
types. The impact of FIH-1 on the localisation of ASPP2 is particularly interesting to study 
under pathophysiological conditions where hypoxic conditions are encountered. The  
ASPP2-Par-3 interaction in endothelial cells which has not been studied to date may be an 
interesting model to study the impact of FIH-1 as hypoxia increases e.g. the permeability of 
the blood brain barrier after ischemic injury (Natah et al., 2009; Lochhead et al., 2010). This 
increase in permeability has been shown to be triggered upon reoxygenation due to a 
mechanism involving the response to oxidative stress (Witt et al., 2008). Interestingly, FIH-1 
was found to be highly sensitive to oxidative stress, and peroxide treatment was shown to 
inhibit hydroxylation of HIF-1α and the ARD-containing FIH-1 substrate Rabankyrin-5 
(Masson et al., 2012). Furthermore, expression of FIH-1 was shown to be reduced after 
transient cerebral ischemia in mice (Shang et al., 2011). In addition, FIH-1 overexpression has 
been reported to partially rescue barrier dysfunction in human pulmonary vein endothelial 
cells (Qi et al., 2011). Although the authors suggest that suppression of HIF activity is 
responsible for the beneficial effect of FIH-1, the modulation of ASPP2 interaction may 
provide another mechanism for the protection against barrier dysfunction. Of note, the 
disruption of barrier function upon oxidative stress has also been reported for epithelial cells 
(Bailey et al., 2004; Gonzalez et al., 2009; Elamin et al., 2013) where ASPP2 has already 
been demonstrated to be important for tight junction formation and maintenance (Cong et al., 
2010; Sottocornola et al., 2010).  
In vitro, we were not able to show substantial effects of FIH-1 on proliferation, apoptosis, 
migration and adhesion of cultured cancer cells. However, the restrictive function of epithelia 
or the blood brain barrier, as the interaction between ASPP2 and Par-3 was shown to affect 
CNS development, are difficult to reproduce in vitro. Despite the limitations of in vitro 
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models, our results may encourage further studies on in vivo disease models which are 
potentially more suitable to assess the physiological consequences of FIH-1-dependent 
hydroxylation of ASPP2 particularly on the integrity of cell-cell junctions. 
Besides a possible impact on barrier function, the regulation of cell contact formation or 
maintenance by FIH-1-dependent hydroxylation of ASPP2 might also affect cancer 
progression in vivo because loss of cell-cell contacts as well as oxidative stress and hypoxia 
contribute to epithelial to mesenchymal transition of cancer cells (Cannito et al., 2008; 
Tamiya et al., 2010).  Although the proliferation of cancer cells has previously been shown to 
decrease upon suppression of FIH-1 in some cell types (Pelletier et al., 2011), a temporary 
decrease in FIH-1 activity is maybe sufficient to disrupt cell-cell contacts via impaired 
interaction of ASPP2 and Par-3. In this context it is interesting to further study the influence 
of FIH-1-dependent hydroxylation of ASPP2, and potentially ASPP1, on binding of further 
protein interaction partners. Both proteins were found to be implicated in the regulation of the 
Hippo signalling pathway which has also been shown to be involved in cell-cell contact 
dependent inhibition of proliferation (Zhao et al., 2007; Ota and Sasaki, 2008; Liu et al., 
2010c). As the deregulation of Hippo signalling can also contribute to epithelial to 
mesenchymal transition, the protein interactions of ASPP2 with components of this pathway, 
PP1 and YAP, may also be regulated by hypoxia via FIH-1. In addition, the recently 
identified interaction of ASPP2 with Ras may potentially also be modulated by FIH-1. In fact, 
initial metabolic labelling experiments performed to identify affected protein interactions 
suggested additional alterations for ASPP2 binding to other proteins than Par-3, e.g. a protein 
of 45 kDa. Although these results were not reproducible, this may be a hint to further FIH-1-
dependent variations in the interaction profile of ASPP2.  
A regulation of multiple signalling pathways by FIH-1 through modulation of protein 
interactions might also provide an explanation for the cell type specific effects on cancer cell 
proliferation. Although the physiologic effects of FIH-1-dependent hydroxylation of ASPP2 
remain to be explored our study suggests that hydroxylation may in general affect protein 
interactions of ARD-containing substrates of FIH-1. Thus quantitative interaction proteomic 
analyses (Trinkle-Mulcahy et al., 2008; Wepf et al., 2009) on the interaction profile of ARD-
containing proteins in the presence and absence of FIH-1 may be a useful tool to further study 
the impact of hydroxylation on other protein interactions not only for ASPP2 but also for 
other ARD-containing FIH-1 substrates. 
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Hydroxylation by Fe(II)- and 2-oxoglutarate-dependent dioxygenases is increasingly 
recognised as an important protein modification. FIH-1-dependent hydroxylation of HIF-α 
subunits has previously been shown to influence the interaction of this protein with important 
transcriptional co-activators thereby modulating HIF transcriptional activity. Recently, 
another substrate group could be identified for FIH-1. All substrates of this new group are 
hydroxylated within a highly conserved protein interaction domain, the ankyrin repeat domain 
(ARD).  
In our study, we identified a single hydroxylation site for FIH-1 within the ARD of apoptosis-
stimulating p53 binding protein 2 (ASPP2), N986, in vitro and in cells. In contrast, the highly 
conserved family member inhibitory ASPP (iASPP) was not hydroxylated by FIH-1 at the 
corresponding asparagine in vitro revealing distinct characteristics required for the 
hydroxylation site despite rather low substrate specificity previously reported for FIH-1. 
Physiologic effects of ASPP2 hydroxylation were studied in cancer cells depleted of FIH-1 by 
lentiviral transduction. Interestingly, p53-dependent apoptosis which has previously been 
shown to be modulated by ASPP2 as well as the interaction between p53 and ASPP2 were not 
affected by silencing of FIH-1. In general, a role for endogenous ASPP2 in the induction of 
chemotherapy-induced apoptosis could not be confirmed using wild-type p53 cancer cells. In 
addition, neither proliferation nor adhesion or migration were affected substantially upon 
FIH-1 depletion. In contrast, the interaction of ASPP2 with the tight junction protein 
partitioning defective 3 homolog (Par-3) was impaired upon suppression of FIH-1. This 
interaction was previously found important for the regulation of polarity and proliferation of 
neuronal progenitor cells in vivo and for the formation and maintenance of tight junctions of 
epithelial cells in vitro. In our study, we observed that the interaction between ASPP2 and 
Par-3 is impaired following silencing of FIH-1which leads to changes in the intracellular 
localisation of the protein complex in a cell type dependent manner. These findings 
demonstrate for the first time an impact of FIH-1-dependent hydroxylation on  
ARD-containing FIH-1 substrates. In contrast to HIF-α where hydroxylation of N803 prevents 
the association with transcriptional co-activators, the interaction of ASPP2 and Par-3 and the 
junctional localisation of both proteins was triggered by FIH-1-dependent hydroxylation. 
Depletion of FIH-1 as well as incubation with the hydroxylase inhibitor 
dimethyloxalylglycine (DMOG) in part disrupted the interaction and the interdependent 
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junctional localisation of ASPP2 and Par-3. Although cancer cell adhesion and migration 
were not altered in vitro, FIH-1-dependent hydroxylation of ASPP2 may well affect the 
integrity of tight junctions and the barrier function of epithelia in vivo. Thus further in vivo 
studies are required to examine the physiologic effects of FIH-1-depletion. Furthermore, the 
role of the interaction between ASPP2 and Par-3 may be interesting to study in other cell 
types as to date all studies were performed in epithelial cells exclusively. Taken together, our 
results demonstrate that protein interactions of ARD-containing FIH-1 substrates can be 
modified by hydroxylation. This is likely to apply to other FIH-1 substrates indicating 
implications for FIH-1 in a broad range of cellular signalling pathways where  
ARD-containing proteins are involved. 
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Die posttranslationale Hydroxylierung durch Fe(II)- und 2-Oxoglutarat-abhängige 
Dioxygenasen wird zunehmend als bedeutsame Protein-Modifikation anerkannt. Es wurde 
z.B. gezeigt, dass FIH-1-abhängige Hydroxylierung von HIF-α Untereinheiten die Interaktion 
mit Co-Aktivatoren beeinflusst und dadurch die transkriptionelle Aktivität von HIF reguliert. 
Drüber hinaus wurde kürzliche eine neue Gruppe von FIH-1-Substraten entdeckt, die alle in 
einer hochkonservierten Protein Interaktionsdomäne, der Ankyrin Repeat Domäne (ARD), 
hydroxyliert werden. 
In dieser Arbeit wurde ein neues Substrat von FIH-1, Apoptose-stimulierendes p53-bindendes 
Protein 2 (ASPP2) identifiziert und charakterisiert. Es wurde gezeigt, dass N986 in der ARD 
von ASPP2 sowohl in vitro als auch in kultivierten Zelllinien durch FIH-1 hydroxyliert wird. 
Im Gegensatz dazu wurde ein hochkonserviertes Mitglied der gleichen Proteinfamilie, 
inhibitorisches ASPP (iASPP) in vitro nicht durch FIH-1 modifiziert. Dies belegt, dass, 
obwohl bereits einige ARD Proteine als Substrate identifiziert wurden und das Enzyme eine 
hohe Variabilität der Hydroxylierungsstelle toleriert, bestimmte Voraussetzungen für die 
Hydroxylierung durch FIH-1 gegeben sein müssen und die Reaktion mit einer gewissen 
Spezifität erfolgt. 
Die physiologischen Effekte der FIH-1-abhängigen Hydroxylierung von ASPP2 wurden in 
Krebs-Zelllinien, in denen die Expression des Enzyms durch lentivirale Transduktion von 
shRNA supprimiert wurde, untersucht. Obwohl ASPP2 als Regulator der p53-abhängigen 
Apoptose identifiziert wurde, hatte die Suppression von FIH-1 keinen Einfluss auf diesen 
Signalweg und auch die Interaktion zwischen ASPP2 und p53 wurde durch Silencing von 
FIH-1 nicht beeinflusst. Generell hatte endogenes ASPP2 keinen Einfluss auf die 
Stressantwort von p53-profizienten Zellen nach Behandlung mit verschiedenen 
Chemotherapeutika. Darüber hinaus waren auch Proliferation, Adhäsion und Migration nach 
Suppression von FIH-1 im Wesentlichen unverändert. Im Gegensatz dazu war die Interaktion 
zwischen ASPP2 und dem Tight Junction Protein partitioning defective 3 Homolog (Par-3), 
welche sowohl für die Regulation der Zellpolarität und der Proliferation neuronaler 
Vorläuferzellen in vivo als auch für die Ausbildung und Aufrechterhaltung von Tight 
Junctions in Epithelzellen in vitro von Bedeutung ist, durch Suppression von FIH-1 
beeinträchtigt. In dieser Arbeit konnten wir nachweisen, dass die reduzierte Interaktion von 
ASPP2 und Par-3 nach Depletion von FIH-1 zu einer Umverteilung beider Proteine innerhalb 
der Zelle führt, wobei ASPP2 und Par-3 nicht länger vorwiegend an Zell-Zell-Kontakten 
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lokalisiert sind. Somit konnten wir zum ersten Mal einen Nachweis für die Funktion der 
Hydroxylierung von ARD Proteinen erbringen. Wie im Falle von HIF beeinflusst  
FIH-1-abhängige Hydroxylierung die Assoziation von ASPP2 mit Interaktionspartnern. Im 
Gegensatz zu HIF-α Untereinheiten, deren Hydroxylierung durch FIH-1 die Interaktion mit 
transkriptionellen Co-Aktivatoren hemmt, fördert FIH-1-abhängige Hydroxylierung  
Zelltyp-spezifisch die Interaktion zwischen Par-3 und ASPP2. Der gleiche Effekt wurde auch 
durch den Hydroxylase-Inhibitor Dimethyloxalylglycin (DMOG) erzielt, was den Effekt 
eindeutig auf die Aktivität des Enzyms und somit die Modifikation zurückführt. Obwohl 
weder Adhäsion noch Migration der Zellen in vitro von der Suppression von FIH-1 
beeinflusst waren, ist es möglich, dass beispielsweise die Integrität und Barriere-Funktion von 
Epithelien in vivo beeinträchtigt ist. Daher sind weiterführende in vivo Studien erforderlich, 
um den physiologischen Effekt der veränderten Lokalisation und Interaktion von ASPP2 und 
Par-3 aufzuklären. Außerdem wäre es interessant, die Interaktion von ASPP2 und Par-3, die 
bisher nur in Epithelzellen untersucht wurde, sowie den Einfluss von FIH-1 in anderen 
Zelltypen zu charakterisieren. Zusammenfassend konnten wir am Beispiel von ASPP2 zeigen, 
dass Proteininteraktionen von ARD-Proteinen durch FIH-1-abhängige Hydroxylierung 
reguliert werden können. Dies könnte nicht nur auf ASPP2 zutreffen, sondern auch auf andere 
ARD-Proteine. FIH-1-abhängige Hydroxylierung könnte somit eine Vielzahl zellulärer 
Signalwege, in denen ARD-Substrate involviert sind, durch Modulation von 
Proteininteraktionen regulieren. 
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8.1 Abbreviations 
2-OG  2-oxoglutarate 
53BP2  p53 binding protein 2 
aa  amino acids 
ACN  acetonitrile 
AGC  automatic gain control 
AJC  apical junctional complex 
AM  acetoxymethyl ester 
Amc  7-amino-4-methylcoumarin 
AnkyrinR erythrocyte ankyrin 
ANOVA analysis of variance 
APCL  adenomatous polyposis coli protein 2 
ape-1  apoptotic enhancer 1 protein 
aPKC  atypical protein kinase C 
APP-BP1 amyloid β precursor protein-binding protein 1 
APS  ammonium persulfate 
ARD   ankyrin repeat domain 
ASB4  ankyrin repeat and SOCS box protein 4 
ASPP  apoptosis-stimulating p53 binding protein 
ATP  adenosine triphosphate 
Bbp  Bcl-2 binding protein 
BCA  bicinchoninic acid 
Bcl-2  B-cell lymphoma 2 
Bcl-W  Bcl-2-like protein 2 
Bcl-XL  B-cell lymphoma-extra large 
bHLH   basic helix-loop-helix domain 
Bnip3  Bcl-2/adenovirus E1B 19kDa interacting protein 3 
bp  base pairs 
BSA  bovine serum albumin 
Ca-9  carbonic anhydrase 9 
CagA  cytotoxin-associated gene A 
CBP  CREB binding protein 
CDB3  cytoplasmic domain of band 3 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate 
CHX  cycloheximide 
CNS  central nervous system 
cpm  counts per minute 
CREB  cAMP responsive element-binding 
CTAD  C-terminal transactivation domain 
Cu  Curie 
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DAPI  4',6-diamidino-2-phenylindole 
DDA3  proline serine-rich coiled-coil protein 1 
DDX42 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 
Dlg1  drosophila disc large tumor suppressor 
DMEM dulbecco´s modified eagle medium 
DMOG dimethyloxalylglycine 
DMSO dimethylsulfoxid 
DNA  deoxyribonucleic acid 
dNTP  deoxynucleotide triphosphate 
Doxo  doxorubicin 
DSMZ  Deutsche Sammlung von Mikroorganismen und Zellkulturen 
DSP  dithiobis[succinimidylpropionate] 
DTT  dithiothreitol 
ECL  enhanced chemiluminescence 
EDTA  ethylenediaminetetraacetic acid 
EMT  epithelial to mesenchymal transition 
Eto  etoposide 
FBS  fetal bovine serum 
FEM1β fem-1 homolog B 
FGIF  fibroblast growth inhibitory factor 
Fig.  figure 
FIH-1  factor inhibiting HIF-1 
GABP  GA-binding protein 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
Glut-1   glucose transporter 1  
GST  glutathione S-transferase 
GTAR  gene trap ankyrin repeat 
GTP  guanosine triphosphate 
Gy  Gray 
HCD  higher-energy collisional dissociation 
HCV  hepatitis-C-virus 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIF  hypoxia-inducible factor 
hMASK human mammalian STE20-like protein kinase 4 
HPLC  high-performance liquid chromatography 
HRas  Harvey rat sarcoma 
HRE  hypoxia-responsive element 
HRP  horseradish peroxidase 
iASPP  inhibitory ASPP 
ILK-1  integrin-linked kinase 1 
INK  inhibitor of cyclin-dependent kinase 
IPTG  isopropyl β-D-1-thiogalactopyranoside 
IRS-1  insulin receptor substrate 1 
IκBα  NF-κB inhibitor α 
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kDa  kilodalton 
L  linker region 
LATS  large tumor suppressor 
LB  Luria Broth 
LC  liquid chromatography 
mmu  milli mass units 
mRNA messenger RNA 
MS  mass spectrometry 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW  molecular weight 
MYPT1 myosin phosphatase target subunit 1 
NF-κB  nuclear factor kappa-light-chain-enhancer of activated B-cells 
NOG  N-oxalylglycine 
NP-40  Nonidet P-40 (octylphenoxypolyethoxyethanol) 
NTAD  N-terminal transactivation domain 
OD  optical density 
ODD  oxygen-dependent degradation domain 
p.a.  pro analysis 
PAGE  polyacrylamide gel electrophoresis 
Par-3  partitioning defective 3 homolog  
Par-6  partitioning defective 6 homolog  
PAS   Per-Arnt-Sim domain  
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PDZ  PSD95, Dlg1, ZO-1 motif 
Pfu  Pyrococcus furiosus 
PGK1  phosphoglycerate kinase 1  
PHD  prolyl hydroxylase domain containing protein 
PMSF  phenylmethylsulfonyl fluoride 
PP1  serine/threonine-protein phosphatase 1 
ppm  parts per million 
Pro  proline-rich region 
PSD95  post synaptic density protein 
PUMA p53 upregulated modulator of apoptosis 
PVDF  polyvinylidene fluoride 
RAD  Ras-associated domain 
RAI  RelA-associated inhibitor 
Ras  rat sarcoma 
REG  regulatory domain 
RelA  NF-κB subunit p65 
RNA  ribonucleic acid 
RNaseL ribonuclease L 
rpm  rounds per minute 
RPMI  Roswell Park Memorial Institute 
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SDS  sodium dodecyl sulphate 
SH3  Src-homology 3 
shRNA small hairpin RNA 
siRNA  small interfering RNA 
SOCS  suppressor of cytokine signalling 
Src  sarcoma 
SV40  simian virus 40 
TAD  transactivation domain 
TAE  Tris-acetate-EDTA buffer 
Taq  Thermus aquaticus 
TAZ  transcriptional co-activator with PDZ-binding motif 
TBS  Tris buffered saline 
TCA  trichloroacetic acid 
TEAD  TEA domain 
TEMED tetramethylethylenediamine 
TER  transepithelial electrical resistance 
TET  tetramerisation domain 
TFA  trifluoroacetic acid 
TRPV4 transient receptor potential cation channel subfamily V member 4 
U  units 
Ub  ubiquitin 
Ubl  ubiquitin-like fold 
VHL  von Hippel-Lindau 
XIC  extracted ion chromatogram 
YAP  Yes-associated protein 
Yes  tyrosine-protein kinase 
ZO-1  zonula occludens-1 
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